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Antibodies are essential molecules for diagnosis and treatment of diseases caused by
pathogens and their toxins. Antibodies were integrated in our medical repertoire against
infectious diseases more than hundred years ago by using animal sera to treat tetanus and
diphtheria. In these days, most developed therapeutic antibodies target cancer or
autoimmune diseases. The COVID-19 pandemic was a reminder about the importance
of antibodies for therapy against infectious diseases. While monoclonal antibodies could
be generated by hybridoma technology since the 70ies of the former century, nowadays
antibody phage display, among other display technologies, is robustly established to
discover new human monoclonal antibodies. Phage display is an in vitro technology which
confers the potential for generating antibodies from universal libraries against any
conceivable molecule of sufficient size and omits the limitations of the immune systems.
If convalescent patients or immunized/infected animals are available, it is possible to
construct immune phage display libraries to select in vivo affinity-matured antibodies. A
further advantage is the availability of the DNA sequence encoding the phage displayed
antibody fragment, which is packaged in the phage particles. Therefore, the selected
antibody fragments can be rapidly further engineered in any needed antibody format
according to the requirements of the final application. In this review, we present an
overview of phage display derived recombinant antibodies against bacterial, viral and
eukaryotic pathogens, as well as microbial toxins, intended for diagnostic and
therapeutic applications.
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Antibodies are indispensable tools for basic research (Colwill and
Gräslund, 2011), diagnostics (Kourea and Kotoula, 2016) and
therapy (Kaplon and Reichert, 2021). In the past - and still today -
polyclonal antibodies (blood serum) are produced in animals like
horses (von Behring and Kitasato, 1890). The hybridoma
technology was a milestone in antibody generation because it
allowed the production of monoclonal antibodies (Köhler and
Milstein, 1975). Despite these antibodies are monoclonal, cell
secreted antibodies are not always monospecific, as unveiled by
the results of a multicentric study on the detrimental effects of
genetic diversity in individual hybridoma clones (Bradbury et al.,
2018). Of 185 randomly selected hybridomas analyzed in this
study, almost one third was found to contain additional
productive heavy or light chains, resulting in antibodies with
reduced affinity and more than one specificity. Other limitations
of the hybridoma technology are the possible instability of the
tetraploid, but also often aneuploid hybridoma cell lines (Pauza
et al., 1993), the restriction of the immune system which prevents
the generation of antibodies against highly conserved or self-
antigens and most important the limitations to directly generate
human antibodies (Winter and Milstein, 1991). The hybridoma
technology most commonly provides murine antibodies for use in
research and diagnostics. But, the therapeutic applications of
murine antibodies are very limited because repeated
administration of murine antibodies can cause a human anti-
mouse antibody reaction (HAMA), which can lead also to severe
side effects such as anaphylactic shock (Courtenay-Luck et al.,
1986). While various humanization strategies are available to
reduce the immunogenicity, these approaches are often
laborious (Almagro and Fransson, 2008; Lo K.-M. et al., 2014).
The human hybridoma technology allows the generation of
human antibodies, (Cole et al., 1984; Hammond, 2010), but this
approach will not be able to deliver antibodies against any targets
because specific B-cells from humans would be needed and this is
limited by ethical constraints. An alternative for human antibody
generation is the use of transgenic animals in which the animal
antibody gene repertoire is substituted with the corresponding
human gene repertoire, but also this technology is limited by the
restrictions of the immune system. This approach was successfully
used for several approved therapeutic antibodies (Jakobovits, 1995;
Lonberg and Huszar, 1995; Fishwild et al., 1996; Nelson
et al., 2010).
A technology which allows to generate fully human antibodies
right away, hence avoiding the side effects originating fromHAMA,
is antibody phage display. Because this approach uses an in vitro
selection process, it does not have to rely on immunization and
associated limitations, and can use entirely humangene repertoires.
Phagedisplay isbasedon theworkofGeorgP. Smithonfilamentous
phage, which infects E. coli and it is the most commonly used
antibody display approach nowadays (Smith, 1985). Referring to
the pan and the method of gold diggers, the antibody selection
process was called “panning” (Parmley and Smith, 1988).
Around 1990/91, the M13 phage display technology was
further developed for human antibody generation in parallel atFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 2three research sites: DKFZ in Heidelberg (Germany), MRC
Laboratory of Molecular Biology in Cambridge (UK) and at the
Scripps Research Institute in La Jolla (USA) (McCafferty et al.,
1990; Barbas et al., 1991; Breitling et al., 1991; Clackson et al.,
1991). For the expression of the antibody::pIII (phage protein III)
fusion proteins via phage display, two different genetic approaches
have been developed. Initially, the antibody genes were directly
inserted into the M13 phage genome and fused upstream of the
wildtype pIII gene (gIII) (McCafferty et al., 1990). Due to a better
genetic stability and opportunity for independent regulation of
phage and antibodies production, today the most successful
system is based on phagemids. These are independent plasmids
which provide the genes encoding the antibody::pIII fusion
proteins and contain a phage morphogenetic signal for
packaging of the phagemid into the phage particles (Breitling
et al., 1991). In both phage display systems, the antibody
fragments are always displayed on the phage surface and the
corresponding antibody gene is packaged into the same phage
particle. This successful technology was awarded with the Nobel
Prize for Chemistry in 2018. For antibody phage display, the most
common used antibody formats are the single chain fragment
variable (scFv) (Vaughan et al., 1996; Schofield et al., 2007; Hust
et al., 2011) or fragment antigen binding (Fabs) (de Haard et al.,
1999; Hoet et al., 2005). Other used formats are human VH
domains (dAbs), immunoglobulins of sharks (IgNARs) and the
variable domains of camel heavy chains (VHHs) (Muyldermans,
2001; Nuttall et al., 2001; Holt et al., 2003; Nuttall et al., 2004;
Muyldermans et al., 2009). The use of immune camel, llama or
alpaca libraries gained popularity in the last five years. For
veterinary research, chicken antibody libraries are often used
(Fehrsen et al., 2005; Foord et al., 2007; Wemmer et al., 2010).
The diversity of chicken antibody genes is the result of gene
conversion. Here, the N- and C-terminal parts of chicken’s VH
and VL are always identical, which facilitates antibody gene
amplification and library cloning (Parvari et al., 1988; Chiliza
et al., 2008).
In the antibody selection process (panning), in most cases, the
target molecules is immobilized on a solid surface, like plastic
surfaces - normally used for ELISA - such as polystyrene tubes or
microtiter plate wells, the latter of which is the most simple and
commonly used method (Hust et al., 2002; Russo et al., 2018),
affinity chromatography column matrixes (Breitling et al., 1991)
or magnetic beads (Sawyer et al., 1997). An alternative is the use
of biotinylated targets for a selection in solution followed by a
“pull-down” with streptavidin beads (Schütte et al., 2009; Wenzel
et al., 2020b). After incubating the entire diversity of the phage
display library with these immobilized antigens, the tremendous
excess of non- or weak-binding antibody phage particles are
removed by stringent washing. Afterwards, the bound antibody
phage will be eluted, mainly by trypsinization or by pH shift, and
used for E. coli infection. Subsequently, the phagemid bearing
E. coli will be infected with a helperphage to produce new
antibody phage particles with an enriched fraction of antigen
specific antibody phage clones. Usually 3-5 panning rounds are
performed before screening. Specific binders can be identified in
a screening process using monoclonal soluble antibodies orJuly 2021 | Volume 11 | Article 697876
Roth et al. Recombinant Antibodies Against Infectious Diseasesmonoclonal antibody phage by e.g. ELISA (Frenzel et al., 2014),
WB (Hust et al., 2002) or flow cytometer (Ayriss et al., 2007). The
antibody fragment genes can be subcloned to produce antibodies
in any desired antibody format, e.g. IgG or scFv-Fc (Hoet et al.,
2005; Dübel et al., 2010; Hust et al., 2011; Jäger et al., 2013;
Frenzel et al., 2014). Figure 1 shows an overview on the phage
display antibody selection process. An overview about phage
display in comparison to other display technologies is given by
Valldorf et al. (2021).
Depending the origin of the V-gene repertoires, there are two
types of libraries: immune libraries and universal libraries.
Immune libraries are constructed from convalescent patients
or immunized donors. This library type is most used to obtain an
antibody against a particular target, e.g. an infectious pathogen
like Ebola virus (Maruyama et al., 1999a) or diphtheria toxin
(Wenzel et al., 2020a). The advantage of this library type is that
the V-genes contain hypermutations and are already affinity-
matured for the targeted pathogen.
The alternatives are universal libraries - in the past also named
“single-pot” libraries - made of naïve, semi-synthetic or synthetic
gene repertoires. This library type allows to isolate antibody
fragments binding to virtually every possible target without the
need for an immunization or the availability of patients’ blood.
(Winter et al., 1994; Dübel et al., 2010; Frenzel et al., 2017). In a
pandemic situation, this provides a source for immediate
antibody generation against a new arising pathogen,
independently from the availability of material from patients
(Bertoglio et al., 2021b). The Naïve libraries are cloned from
rearranged V genes derived from B cells (IgM) of non-immunized
donors. Examples for naïve libraries are the HAL scFv libraries
(Hust et al., 2011; Kügler et al., 2015) and Fab library constructed
by de Haard and colleagues (de Haard et al., 1999).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3Semi-synthetic libraries are cloned from unrearranged V genes
from pre-B cells (germline cells) (Griffiths et al., 1994) or in most
cases from one antibody framework (Pini et al., 1998). In this
defined framework one or several CDRs, but always the CDR H3,
are randomized, e.g. by using DNA-primers covering the CDR
H3 section. The semi-synthetic libraries Tomlinson I and J
libraries are often used and are the best example for semi-
synthetic libraries. These libraries have a VH3-23 and Kappa
IKV1-39 framework combined with randomized CDR2 and
CDR3 (de Wildt et al., 2000). For the FAB310 antibody gene
library, a combination of naïve and synthetic repertoire was used.
Here, the Fd fragment (VH+CH1) contains randomized CDR1
and CDR2 in the human VH3-23 framework and a naïve CDR3
regions from autoimmune patients. The Fd fragments were
combined with light chains also from autoimmune patients
(Hoet et al., 2005). The transition of semi-synthetic to synthetic
libraries is not strict. In general, complete synthetic libraries are
made of human frameworks and here all CDR cassettes are
synthetic, the best examples are the HUCAL libraries (Hayashi
et al., 1994; Knappik et al., 2000; Tiller et al., 2013). Universal
libraries have a theoretical diversity higher than 1010 independent
clones (Schofield et al., 2007; Glanville et al., 2009; Lloyd et al.,
2009; Tiller et al., 2013; Kügler et al., 2015).
In vitro display methods, like phage display, differ from classical
animal immunization approaches to obtain polyclonals or
hybridomas, in the possibility to directly generate sequence
defined monoclonal antibodies. Additionally, the phage display
antibody selection process occurs entirely in vitro and its
customization allows to pre-filter antibodies with the intended
binding properties, such as epitope specificity, binding at defined
pH and temperatures, or absence of unwanted cross-reactivities. An
alternative method that allows to generate sequence definedFIGURE 1 | Schematic illustration of the antibody generation process. For the antibody generation, human phage display libraries or libraries from other species are
used. These libraries will be used for the in vitro selection (panning) on a target molecule. In short: the antibody phage particles will be incubated with target molecule
(in the illustration, a target molecule was immobilized in a microtitre plate well and a scFv phage display library is used), the non and weak binding antibody phage
particles will be washed away and the binding antibody phage will be eluted (the procedure will be repeated 3-5 times) and further analyzed. In the next step,
monoclonal binders will be identified, e.g. by ELISA. Finally, the selected antibody fragments can be recloned, because the corresponding gene is packaged in the
phage particles, and produced in any antibody format tailored to the final application.July 2021 | Volume 11 | Article 697876
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et al., 2018). B-cells secreted antibodies binding to labeled antigen
material can be assessed at single cell level in droplets of buffer
solution. This method, very laborious and technically demanding, is
restricted to the availability of patient or immunized animal B-cells.
Additionally, this approach provides a lower degree of flexibility in
the number of assays which can be performed in the initial antibody
screening phase. The upside of this method is the possibility to
discover antibodies already in the IgG format. These features made
this method particularly popular for the discovery of therapeutic
antibodies from B-cells of disease-recovered patients. This is the
case of the FDA approved Neutralizing antibodies to Ebola virus
glycoprotein Ebanga (Ansuvimab-zykl) (https://www.fda.gov/
drugs/drug-safety-and-availability/fda-approves-treatment-ebola-
virus), the anti-HIV neutralizing antibodies under clinical
evaluation (Spencer et al., 2021) or the anti-SARS-CoV-2
antibodies REGN10933 and REGN10987 (Hansen et al., 2020).
To date, 106 monoclonal antibodies and antibody conjugates
have been approved by EMA and/or FDA (status March 2021),
87 antibodies are in clinical phase 2 or 3 and 122 antibodies are
in phase 1 or IND filed (Source: antibodysociety.org, status April
2020). Most approved antibodies are for the treatment of
autoimmune diseases and cancer. The annual sales of
therapeutic antibodies exceeded 98 billion US$ in 2017 and the
market will be predicted with 137-200 billion US$ in 2022 (Grilo
and Mantalaris, 2019). The mode of action of therapeutic
antibodies are numerous and include neutralization of
substances e.g. cytokines like tumor necrosis factor alpha
(TNF-a) (Alonso-Ruiz et al., 2008) or toxins (Rasetti-
Escargueil et al., 2017), human cell binding and modulation of
the host immune system (Chatenoud and Bluestone, 2007),
blocking of receptors which are overexpressed on cancer cells
like epidermal growth factor receptor (EGFR) (Peeters et al.,
2009) or combinations of these mode of actions (Adams and
Weiner, 2005). Currently, eight recombinant antibodies or
antibody cocktails are approved for the direct treatment of
pathogens or toxins. The first recombinant antibody approved
for the treatment of an infectious disease was Palivizumab. It is a
classical humanized antibody approved in 1998 for the treatment
of Respiratory syncytial virus (RSV) bronchiolitis (Malley et al.,
1998). For anthrax treatment, the human antibody Raxibacumab
was developed. This antibody is derived from a human phage
display library (made by Cambridge Antibody Technology in
cooperation with Human Genome Science) and was approved in
2012 (Mazumdar, 2009; Kummerfeldt, 2014). A second antibody
for post-exposure treatment of anthrax, the antibody
Obiltoxaximab, has been approved in 2020 (Henning et al.,
2018). A further approved antibody against toxins is
Bezlotoxumab, approved in 2016. This antibody neutralizes the
Clostridioides difficile toxin TcdB (Babcock et al., 2006; Johnson
and Gerding, 2019). The anti-HIV antibody Ibalizumab has been
approved in 2018. The mode of action is very unique for an anti-
viral antibody, because it blocks cell entry by binding to the
human receptor CD4 on the target cells instead of binding to the
virus (Beccari et al., 2019). The anti-rabies antibody Rabishield to
replace anti-rabies serum therapies has been approved 2018 inFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4India (Wang et al., 2011; Gogtay et al., 2018). End of 2020, two
products were approved for the treatment of Ebola: the three-
antibody cocktail REGN-EB3 (Atoltivimab/maftivimab/
odesivimab) (Pascal et al., 2018) and the single antibody
mAb114 (Ansuvimab-zykl) (Corti et al., 2016). These
antibodies showed a good efficiency in clinical trials against
Ebola virus especially in comparison to Remdesivir (Mulangu
et al., 2019). In the COVID-19 pandemic, the anti-SARS-CoV-2
antibody cocktail Casirivimab (REGN10933)/Imdevimab
(REGN10987) (Baum et al., 2020; Hansen et al., 2020) and the
antibody Bamlanivimab (LY-CoV555) (Chen et al., 2021) got a
conditional marketing authorization in Europe and an
Emergency use authorization (EUA) in the USA for non-
hospitalized patients with mild to moderate symptoms. The
FDA also authorized the antibody cocktail Bamlanivimab and
Etesevimab (JS016, CB6) (Shi et al., 2020) in the USA for the
same indication. For the treatment of hospitalized patients with
moderate to severe symptoms, phage display derived antibody
COR-101 (STE90-C11) against SARS-CoV-2 (Bertoglio et al.,
2021a) is in clinical phase 1b/II.
In the next sections, we provide an overview of recombinant
antibodies derived from phage display against bacterial and viral
pathogens, eukaryotic pathogens (parasites, fungi) and toxins, as
well as detailed examples for diagnostics and therapy.RECOMBINANT ANTIBODIES
AGAINST BACTERIA
Toxins are the most frequent antigenic target of therapeutic
antibodies used to fight bacterial pathogens. This topic is
thoroughly discussed in a dedicated paragraph: “targeting of
toxins with recombinant antibodies”. Excluding toxin antigens,
antibodies raised against bacteria are predominantly used in
diagnostics (Skottrup et al., 2011; Ferrara et al., 2012) and to
assess the presence of contamination in environmental samples
(Griep et al., 1998; Mechaly et al., 2008). As of today,
microbiologic bacteria identification by cultivation remains the
benchmark approach for the diagnostic of several pathogenic
bacterial species, including Mycobacterium tuberculosis (Norbis
et al., 2014), Salmonella Typhimurium (Kuhn et al., 2012), or
Listeria monocytogenes (Gasanov et al., 2005).
The many drawbacks of these methods are the low throughput
and high costs caused by their inherently long experimental
duration, the higher risk of exposure to pathogenic organisms
and the need of highly trained personnel. Real-time PCR and
other molecular diagnostics approaches have been introduced to
reduce the time needed for the identification of many bacteria
(Liang et al., 2018), while offering high detection sensitivity and
specificity. Nevertheless, such methods most often depend on the
availability of laboratory infrastructure and, if portable, are less
amenable to high throughput parallelized measurements (Xu
et al., 2020). Similarly, mass spectrometry is able to provide
high sensitivity, however, this technology requires expensive
devices and trained personnel (Dixon et al., 2015). On theJuly 2021 | Volume 11 | Article 697876
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immunochromatography, are faster, simpler, and well-suited for
high-throughput. These features, together with the lower costs
compared to other techniques, contributed to the success of these
diagnostic approaches world-wide, including developing
countries, where resources may be scarce and laboratories
sparsely distributed over the territory.
Up to date, a vast plethora of antibodies for diagnostic
applications has been generated via phage-display against
different bacterial proteins or carbohydrates (Table 1).
Interestingly, research on this field seems to be in constant
rise, as 44% of these antibodies have been generated only in
the past five years.
In the following paragraphs, we offer detailed examples on
antibodies against different bacterial pathogens that were
generated using phage display.
Mycobacterium tuberculosis (Mtb) is the bacteria responsible
for a lung infection known as Tuberculosis (TB). This pathogen
specifically attacks and replicates inside the macrophage cells in
the alveoli, causing fatigue, fever and coughing (Fu and Fu-Liu,
2002). As of 2021, this disease affected approximately 10 million
people and caused 1.5 million deaths worldwide per year (World
Health Organization, 2021). TB early diagnosis is essential to
improve treatment and limit disease spread. The protein secreted
by Mtb in the highest amounts, Antigen 85 (Ag85), represents an
ideal target for diagnostics (Wiker and Harboe, 1992). Ag85 is an
oligomeric protein composed of three relatively small (30-32
kDa) homologue proteins (Ag85A, Ag85B and Ag85C) (Wiker
et al., 1992). In a novel approach described by Ferrara et al.
(2012), a combination of antibody display techniques was
successfully adopted to select Ag85 complex-specific
antibodies. A universal phage display naïve scFv-library with a
nominal diversity of ~1011 unique antibodies was used for initial
selection on Ag85, obtaining a sub-library of 105 pre-selected
antibodies. Second, the selected antigen-specific scFv genes were
used for the generation of yeast-display antibody sub-library.
Upon completion of yeast based antibody generation, each clone
was tested in FACS for its ability to specifically recognize the
antigen target resulting in the discovery of 192 clones having the
desired properties. Sequence analysis revealed that 111 of these
antibodies were unique and could be used in further Ab
characterization. Chessboard antibody combination testing
resulted in the identification of 7 antibody pairs that detect as
little as 22.7 nM Ag85 in patient sera or 6.1 nM in serum free-
conditions. The uniqueness of this work relies in the fact that
each validated antibody was specific for the Ag85-complex only.
Other approaches were aimed at discovering subunit-specific
antibodies, as in the case of Fuchs et al. Here, the naïve HAL7/8
phage display libraries were incubated with recombinant Ag85B
subunit (Fuchs et al., 2014). The resulting antibodies were shown
to have, in sandwich ELISA or lateral flow test, an antigen
protein limit of detection of respectively 10 ng/mL and <5 ng/
mL. Nevertheless, when using bacterial cell extracts or filtered
culture material, immunodetection could be only performed in
ELISA or western blot. The authors concluded that the absence
of an antibody affinity improvement step may have been theFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5reason for their results. This supposition found indirect
confirmation in a different study by Sixholo and colleagues
(Sixholo et al., 2011) describing the selection of antibodies
against the Mtb 16 kDa heat shock protein X (HspX) from
chicken semi-synthetic Nkuku antibody gene library. By the
repetition of four panning rounds against recombinant antigen
material, three unique scFv’s were confirmed to bind HspX in
ELISA. On purpose, the clone with the weakest binding was
chosen for in vitro affinity maturation by different methods. In
the first approach, a mutant library of the parental antibody gene
was generated by error-prone PCR, resulting in a diversity
of ~ 3 × 107 unique scFv clones. Repeating the antibody
selection using this library under more stringent conditions,
led to the discovery of three mutant scFv’s with increased
binding affinity. Direct binding comparison in ELISA showed
that the newly generated antibodies produced a signal ~11 times
higher than the parental clone. The result was confirmed by the
improved association and dissociation kinetics in SPR analysis.
All affinity-improved antibody genes contained mutated amino
acids in both CDR and framework regions. In the second
approach, a glycine residue alone was replaced to the common
15-mer linker connecting the VH to VL, resulting in tetramer
formation (Schmiedl et al., 2006). The avidity effect leading to
cooperative binding resulted in a binding signal increase of ~14
times in ELISA. Antibodies against Mtb were also generated by
Hamidon and colleagues (Hamidon et al., 2018) utilizing a
different approach. A patient immune TB library with a
nominal diversity of 109 different scFv antibodies could be
generated starting from the B-cell material from six individuals
infected with TB. This immune library was used to select
antibodies against Mtb a-crystalline, resulting in three unique
antigen-specific clones validated for antigen binding in ELISA
and Western Blot assays.
Periodontitis is a disease where inflammation of the dental
gum results in its progressive retraction and, if not cured on time,
loss of teeth. One of the major pathogens involved in gum
infection is Porphyromonas gingivalis (Socransky et al., 1998).
The RgpB cysteine proteases secreted by this pathogen is one of
the causing factors of the gum inflammation and constitutes a
valid biomarker candidate (Imamura, 2003). Skottrup et al.
(2011) generated antibodies against immobilized RgpB from a
naïve library of camelid antibodies with a diversity of ~5 x 107
different clones. Such antibodies consist of a monomeric VHH
domain (~15 kDa), which offer multiple advantages for
diagnostics, in particular high yields in E. coli production
systems, good stability and small epitope accessibility. This
library yielded an elite antibody clone with 362 pM affinity
towards the recombinant RgpB, also specific to the antigen
presented on cells. While not inhibiting RgpB catalytic activity,
this antibody showed in subtractive inhibition ELISA a limit of
detection equal to ~8 x 106 cells/mL of saliva.
In the field of foodborne gastrointestinal infection causing
pathogens, Salmonella Typhimurium is probably the most
studied bacteria (Jacobsen et al., 2011). In the attempt to
generate antibodies for the detection of this pathogen, Meyer
et al. (2012) utilized ORFeome phage display for biomarkerJuly 2021 | Volume 11 | Article 697876








Acinetobacter baumannii Bap Immune VHH camel ELISA, WB, in vivo neutralization (Payandeh et al., 2014)
Bacillus anthracis S-layer protein EA1 immune VHH llama ELISA, WB (Walper et al., 2012;
Anderson et al., 2018)
Bacillus anthracis live bacteria immune scFv mice ELISA, WB, IF (Mechaly et al., 2008)
Bacillus anthracis protective antigen (PA) naïve scFv human ELISA, Inhibition assay (Ahn et al., 2019)
Bordetella pertussis filamentous hemagglutinin,
pertactin
immune scFv mice ELISA, in vitro inhibition, in vivo
studies
(Hussein et al., 2007)
Brucella melitensis radiated bacteria immune scFv mice ELISA (Hayhurst et al., 2003)
Campylobacter jejuni whole cells immune scFv rabbit ELISA, WB (Nzuma et al., 2018)
Chlamydophila psittaci 2.4[2.8]2.4-linked Kdo
tetrasaccharide
immune scFv mice ELISA, IF (Gerstenbruch et al., 2010)
Chlamydia trachomatis elementary bodies naïve scFv human ELISA, WB, IF (Sheets et al., 1998;
Lindquist et al., 2002)
Chlamydia trachomatis unknown immune VHH camel unknown (Tillib et al., 2017)
Clostridium botulinum RhoA/B naïve scFv human WB, immunofluorescence (Rohrbeck et al., 2016)
Clostridium difficile different surface proteins
(including FliC and FliD)
semi-
synthetic
scFv human ELISA, WB, in vitro motility assay (Shirvan and Aitken, 2016)
Clostridium difficile Surface layer proteins (SLPs) immune VHH Llama ELISA, WB, in vitro motility assay (Kandalaft et al., 2015)
Escherichia coli live E. coli F17 + immune VHH camel ELISA (Salhi et al., 2020)
Francisella tularensis lipopolysaccharide (LPS) immune scFv, IgG rabbit ELISA, WB, IF, in vitro neutralization (Mechaly et al., 2019)





human ELISA, OPK, IF, in vivo protection (Wang Q. et al., 2016)
Haemophilus influenzae capsular polysaccharide immune Fab human ELISA (Reason et al., 1997)
Helicobacter pylori urease semi-
synthetic
scFv human ELISA, WB, WB (Fouladi et al., 2019)
Helicobacter pylori bacterial lysate immune scFv human ELISA (Reiche et al., 2002)
Lactobacillus acidophilus S-layer protein naïve scFv human FACS, WB (Close et al., 2013)
Lawsonia intracellularis live bacteria semi-
synthetic
scFv human ELISA, IF (Dezorzová-Tomanová
et al., 2007)
Legionella pneumophila whole cells naïve scFv human ELISA, biosensor (Kuhn et al., 2017)
Leptospira spec. LipL21 naïve scFv human ELISA (Mohd Ali et al., 2021)





ELISA (Gene et al., 2015)




human ELISA, WB, IF (Moreira et al., 2020)
Listeria monocytogenes heat-killed cells naive VHH Llama ELISA, WB (Tu et al., 2016)
Moraxella catarrhalis HMW-OMP semi-
synthetic
scFv human ELISA, FACS, WB, in vitro inhibition (Boel et al., 1998)
Mycobacterium avium cell lysate immune scFv sheep ELISA, WB, FACS, IF (Berger et al., 2006)




chicken ELISA, WB (Wemmer et al., 2010)
Mycobacterium leprea PGLI-M3 naïve? scFv human ELISA, immunohistochemistry (Lima et al., 2020)
Mycobacterium
tuberculosis
antigen 16kDa (HspX) semi-
synthetic
scFv chicken ELISA (Sixholo et al., 2011)
Mycobacterium
tuberculosis
antigen 85B naïve scFv,scFv-
Fc
human ELISA, WB, lateral flow strip assay (Fuchs et al., 2014)
Mycobacterium
tuberculosis
antigen 85 naïve scFv,scFv-
Fc
human ELISA (Ferrara et al., 2012)
Mycobacterium
tuberculosis
LAM immune scFv Rabbit/
chicken
Sandwich-ELISA (Kawasaki et al., 2019)
Mycobacterium
tuberculosis
a-crystalline antigen immune scFv human ELISA (Hamidon et al., 2018)
Mycobacterium
tuberculosis
LAM immune scFvIgG rabbit ELISA, WB, dot blot, flow cytometry (Yan et al., 2020)
Neisseria meningitidis NadA Immune VHH llama Dot blot, WB, IHC, blocking assay, in
vitro model
(Kulkarni et al., 2020)
Porphyromonas gingivalis RgpB naïve VHH camel ELISA (Skottrup et al., 2011)
Pseudomonas aeruginosa SpuE naïve scFv human ELISA (Zhang Y. et al., 2019)
Pseudomonas aeruginosa flagelar capping protein (FliD) naïve scFv,
scFv-Fc
human WB (Postel et al., 2016)
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protein fragments library was screened using sera from
Salmonella infected animals. In a second step, the antigens
corresponding to the newly discovered immunogenic proteins
were used to select human antibodies from the naïve HAL gene
libraries. Antibodies are also potent tools for the monitoring of a
vaccination campaign and discrimination of infected from
vaccinated subjects . For the development of DIVA
(Differentiating Infected from Vaccinated Animals) vaccines
against S. Typhimurium, Selke and colleagues (Selke et al.,
2007) generated an engineered bacterial strain lacking the
marker protein OmpD (outer membrane protein D). A
serological test using OmpD-specific antibodies constitutes a
tool to discriminate infected animal from vaccinated ones. Meyer
et al. (2011) generated scFv antibodies against OmpD for antigen
detection in competitive ELISA on swine serum.
Another very prominent foodborne pathogen is Listeria
monocytogenes. This bacterial infection, listeriosis, can cause
severe illness, including meningitis and sepsis when reaching
the systemic circulation. As of today, 13 different L.
monocytogenes serotypes have been discovered, of which type
4b, 1/2a and 1/2b have shown to be the most virulent (Datta and
Burall, 2018). Contaminated food also contains non-pathogenic
Listeria species, making the diagnosis more difficult. Indeed,
their faster growth rate during the enrichment step required for
bacteria detection is the major cause of false-negative results in
Listeria monocytogenes food diagnostics (Besse et al., 2010).
Hence, species-specific immunodiagnostic tools constitute a
necessary resource to improve both L. monocytogenes as well
as Listeria spp. detection. Gene and colleagues (Gene et al., 2015)
used naive and immune camelid antibody libraries for the
selection via phage display of diagnostic nanobodies against
internalin B (InIB), a protein which is strongly involved in
host-cell invasion. Two of the five generated nanobodies, R3-
03 and R3-30, showed picomolar binding affinities to InIB,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7representing a valuable resource for bacteria immunodetection
in poorly concentrated samples. A recent study from Moreira
et al. (2020) described the use in combination of different phage
display techniques to identify new Listeria spp. protein
biomarkers and rise antibodies against them. Initially, the
human naïve antibody display phage library HAL9/10 was
used to generate antibodies against different cell fractions from
L. monocytogenes (cell wall, membrane, and cytoplasm). This
way, four binders were isolated, which allowed the identification
of a novel target for Listeria spp. detection named pyruvate
dehydrogenase complex-enzyme 2 (PDC-E2) by using both
immunomagnetic separation/mass spectrometry (IMS-MS) and
ORFeome phage display. One of these antibodies was also used
in immunofluorescence on non-permeabilized cells confirming
the surface localization of the target. Antibody selection against
PDC-E2 recombinant antigen yielded 16 additional antibodies.
These 20 antibodies were finally tested in indirect ELISA against
a panel of 17 Listeria species (including the most virulent L.
monocytogenes serotypes 4b, 1/2a, and 1/2b) and 16 non-Listeria
species. Two antibodies, GSM313-E9 and GSM313-H8, provided
100% sensitivity and specificity for Listeria spp. detection.
Moreover, the binding region (epitope) of 18 out of the 20
antibodies was identified via single-gene phage display for
epitope mapping, enabling to define the lipoyl domains of
PDC-E2 as the major contributors for the detection through
this target.RECOMBINANT ANTIBODIES
AGAINST VIRUSES
Viruses are in every kind of environment and are able to infect
any sort of host. New viral species are continuously discovered








Ralstonia solanacearum LPS naïve scFv human ELISA, IF, WB (Griep et al., 1998)
Salmonella Typhimurium OmpD naïve scFv human ELISA (Meyer et al., 2011)
Salmonella Typhimurium 5 different immunogenic proteins naïve scFv human ELISA (Meyer et al., 2012)
Staphylococcus aureus FnBPA, ClfA immune scFv bovine ELISA, WB, inhibition assay (Wang M. et al., 2015,
Wang M. et al., 2016)
Staphylococcus aureus cells immune scFvscFv-
Fc
human ELISA, dot blot (Nian et al., 2016)
Streptococcus
pneumoniae
Pep27 synthetic scFv human ELISA (Kim et al., 2018)
Streptococcuspneumoniae PspA synthetic scFv human WB (Jang et al., 2017)
Streptococcus mutans &
sobrinus
live cells synthetic Fab human ELISA, IF, Flow cytometry, in vitro
biofilm assay, in vivo model
(Alam et al., 2018)
Vibrio cholera LPS immune VHH camel ELISA, in vivo challenge (Ebrahimizadeh et al.,
2013)
Vibrio parahaemolyticus VP1694 immune scFv mice ELISA, WB (Wang R. et al., 2014)
Vibrio parahaemolyticus OmpU semi-
synthetic
sdAb human ELISA, in vitro inhibition (Yu et al., 2020)
Yersinia pestis F1 naïve scFv human ELISA (Lillo et al., 2011)July 2021 | VELISA, enzyme linked immunosorbent assays; IHC, immunohistochemistry; IF, immuno fluorescence; FACS, fluorescence-activated cell sorting; WB, western blot.olume 11 | Article 697876
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from universal and immune libraries using phage display
technology. Target for selection of antibodies ranged from
peptides and recombinant viral proteins to complete viral or
pseudoviral particles, leading to the isolation of antibodies
against human pathogenic viruses such as Sin nombre virus
(Velappan et al., 2007), Dengue virus (Cabezas et al., 2008;
Saokaew et al., 2014), Influenza virus (Lim et al., 2008; Sui
et al., 2009), VEEV (Kirsch et al., 2008), Norovirus (Higo-
Moriguchi et al., 2014), SARS coronavirus (Sui et al., 2004),
SARS-CoV-2 (Bertoglio et al., 2021b) or Hepatitis C (Songsivilai
and Dharakul, 1998) from naïve antibody gene libraries.
Alternatively, another source of monoclonal antibodies has
been immune antibody gene libraries constructed from hosts
infected with e.g. Hantavirus (Liang et al., 2001; Koch et al.,
2003), WEEV (Hülseweh et al., 2014), HIV (Mohammadzadeh
et al., 2014; Trott et al., 2014), SARS (Kang et al., 2006), Yellow
fever virus (Daffis et al., 2005) or Influenza virus (Throsby et al.,
2008; Sun et al., 2009). Additionally, semi-synthetic libraries
have been used to generate antibodies against e.g. Influenza virus
(Avnir et al., 2014). Plant viruses have also been addressed for
antibody selections (Ziegler et al., 1995; Hust et al., 2002;
Orecchia et al., 2008), beside human and animal viruses.
Virus-specific antibodies have also been selected from
libraries originating from different species such as those from
macaque (Rülker et al., 2012), chimpanzee (Goncalvez et al.,
2008), llama (Fatima et al., 2014), mouse (Liu H. et al., 2014),
chicken (van Wyngaardt et al., 2004) and human origin
(Tikunova et al., 2012).
The predominant format harnessed for initial selection of
antibodies against viruses has been scFv format (Gould et al.,
2005; Wu et al., 2014), although Fab (Wyrzucki et al., 2014; Zhao
et al., 2014) and VHH libraries (Fatima et al., 2014) were often
used. In a peculiar case, Xiao et al. used the antibody CH2
domain as scaffold to generate binders against gp120 of HIV
(Xiao et al., 2009). In the case of HIV, some unique aspects could
be highlighted as for example that the neutralizing anti-gp41
antibody HK20 has a higher neutralization potency as scFv or
Fab compared to IgG, indicating that the IgG format has more
difficult access to the epitope, due to the formats bigger steric
hindrance (Sabin et al., 2010). Another noteworthy example is
the anti-gp41 VHH 2H10, where a CDR3 tryptophan is not
involved in epitope binding, but resulted essential for virus
neutralization (Lutje Hulsik et al., 2013).
In the following paragraphs, we present detailed examples for
antibody generation and engineering using phage display against
different viral taxa.
Vaccinia virus is the arketypal virus within the genus of
Orthopoxvirus. This virus is with 300x 230 nM a large DNA
virus with a genome of about 0,2 Mb (Malkin et al., 2003).
Among the species included in Orthopoxvirus genus, there are
monkeypox virus, cowpox virus and especially variola virus, the
causative agent of smallpox in humans. Occurrence of natural
smallpox has been eradicated in 1977 thanks to a massive WHO
vaccination program, which started ten years earlier. However,
since no vaccination of the general population is nowadaysFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 8conducted and the use of variola virus as potential threat
following intentional release has renewed the research interest
for safe and effective smallpox vaccines, due to case fatality rates
of 30% or more among unvaccinated subjects (Henderson et al.,
1999). It is assumed that immunity against one poxvirus provides
broad immunity against most of the viral family members given
the high similarity shared among orthiopoxviruses (Earl et al.,
2004; Berhanu et al., 2008). Using an immune scFv phage display
library constructed from vaccinia virus immunized patients,
human vaccinia specific antibodies were isolated. In vitro
plaque-reduction neutralization tests proved that seven of these
antibodies were able to neutralize both, vaccinia and cowpox
virus. Five of them, additionally neutralized monkeypox virus
(Tikunova et al., 2012). Another set of antibodies were selected
from a Fab immune library derived from chimpanzee, vaccinated
with vaccinia virus. After conversion into a chimeric
chimpanzee/human IgG format, antibody 8AH8AL, binding to
vaccinia protein B5, was neutralizing in vitro for vaccinia and
smallpox virus. Its protective effect was assessed in mice
challenged with vaccinia virus even when the monoclonal
antibody was administered 2 days after challenge. In this
model, 8AH8AL provided significantly greater protection than
that of the previously isolated rat anti-B5 antibody 19C2 (Chen
et al., 2006). Since experimental work with smallpox virus is
extremely restricted and essentially not allowed, vaccinia had to
be used as model.
Ebola Virus and Marburg Virus, two members of the
Filoviridae family, cause severe hemorrhagic fevers and
extremely high mortality of up to 90% in infected humans.
Besides the obvious public health concern associated with its
natural outbreaks, Ebola virus might be considered a potential
agent of biological warfare and bio-terrorism (Goodchild et al.,
2011). Phage display-derived human antibodies targeting Ebola
virus were selected from an immune library originated from
survivors of the 1995 Ebola virus outbreak in Kikwit, Democratic
Republic of Congo (Maruyama et al., 1999b). Nucleoprotein,
envelope glycoprotein and secreted envelope glycoprotein
binders have been isolated in this study. Antibody (KZ52),
recognizing the envelope glycoprotein, neutralized in vitro
both, as Fab (50% neutralization at 0.4 µg/mL) as well as full
IgG (90% neutralization at 2.6 µg/mL) (Maruyama et al., 1999a).
Follow-up studies demonstrated effective protection in vivo in a
guinea pig Ebola challenge model, upon administration of the
antibody up to one hour post viral challenge (Parren et al., 2002).
Unfortunately, KZ52 showed no protection in macaques
challenged with Ebola, even though the antibody was given in
a two-dose regimen with the first dose one day prior viral
challenge and the second after three days the former dose
(Oswald et al., 2007). Further examples of antibodies selected
through phage display against Filoviridae family members
encompass a murine scFv and two shark IgNAR V immune
libraries generated against inactivated Zaire Ebola virus to yield
several antibodies specific for the viral matrix protein VP40 and
the viral nucleoprotein (Goodchild et al., 2011). Of note, this
work is the first example of a successful targeted IgNAR V
isolation from a shark immune library. The antibodyJuly 2021 | Volume 11 | Article 697876
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of Ebola Sudan virus (SUDV) showed 100% in vivo protection in
scFv-Fc format in a mice challenge model. After 35 days post
infection, the mice were challenged again with SUDV and all
mice survived showing the development of an own protective
immune answer against SUDV (Froude et al., 2017). These
antibodies were also tested as IgG and the X10H2 antibody
was successfully employed in a cocktail with the non-phage
display derived antibody 16F6 (Herbert et al., 2020).
Recombinant antibodies against Marburg virus were generated
using human synthetic libraries (Amatya et al., 2019) or macaque
immune libraries (Froude et al., 2017). The macaque antibodies
showed in vitro neutralization and up to 100% in vivo protection
against wt Ci67 Marburg virus in a prophylactic mice challenge
model using 100 µg scFv-Fc/mice.
Flaviviridae family member Dengue virus (DENV) causes at
least 100 million symptomatic infections each year and became a
major health and economic burden in over 50 countries
worldwide (Moreland et al., 2010; de Alwis et al., 2012;
Moreland et al., 2012). Its genome encompasses a single open
reading frame, contained in the ~ 11 kb positive strand RNA.
The four circulating serotypes of DENV show approximately
70% sequence homology (Moreland et al., 2012; Zhao et al.,
2014). DENV infection can result in clinical symptoms that
include dengue fever, dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS) (Yamanaka et al., 2021), which
is presumably promoted by antibody-dependent enhancement
(ADE) (Taylor et al., 2015). ADE results from partially or non-
neutralizing anti-dengue IgG antibodies from a former infection
mainly of another dengue serotype. The presence of ADE is
associated with the onset of DHF that can be fatal (Halstead,
2014). Two Fabs, namely 5H2 and 5D9, were isolated from a
chimpanzee immune library and neutralized dengue type 4 virus
in a plaque reduction neutralization test (Men et al., 2004). In
another example, human scFv antibodies specific to dengue virus
envelope protein were selected by panning against recombinant
full length envelope protein and its domain III (Saokaew et al.,
2014). Because DENV envelope protein plays an essential role in
virion assembly and viral entry, scFvs selected in this study were
shown to block DENV infection in vitro (Saokaew et al., 2014).
Dengue nonstructural protein 5 (NS5) is involved in viral
replication and host immune response modulation. A naïve
human Fab-phage library was screened for NS5-specific
antibodies using various NS5 variants from Dengue Virus
serotypes 1-4 as antigens for panning and characterization
(Zhao et al., 2014). Alternating the use of NS5 derived from
different dengue serotypes for each selection round, this strategy
allowed the identification of two monoclonals that are cross-
reactive against all four dengue serotypes. Another study
presented antibodies selected against antigen Dengue virus
particles directly captured from supernatant of infected Vero
cells. Here, highly serotype specific antibodies were generated.
Seven out of nine antibodies were specific to only one DENV
serotype. One Dengue-3 selected clone cross-reacted with
Dengue 1, whereas another clone showed pancross-reactivity
despite being selected on Dengue 2 particles. Interestingly, all ofFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 9the obtained antibodies recognized several strains of distinct
genotypes within the corresponding serotype (Cabezas et al.,
2008). Antibody C9 was isolated after panning against dengue
envelope protein using a mouse/human chimeric Fab library.
The antibody crossreacts with DENV1-3 and neutralizes DENV2
in cell-based assays after conversion into full length IgG
(Moreland et al., 2012). Besides scFv and Fab, also variable
domain heavy-chain antibodies (VHH antibodies) have been
selected using phage display technology to target DENV2 NS1
protein. After four rounds of panning, 20 hits were selected
(Fatima et al., 2014). A VHH antibody combination was
developed which allows the detection of NS1 of all four
Dengue strains (Shriver-Lake et al., 2018). For the therapy of
dengue, the application of full-length antibodies like IgG may not
provide the best solution for dengue therapy in the context of
ADE. Antibodies with a silent Fc part or antibody fragments
would be the preferred option for the development of therapeutic
antibodies against dengue.
Venezuelan equine encephalitis virus (VEEV), an alphavirus
of the Togoviridae family, causes both equine epidemics and also
encephalitis in humans (Johnson and Martin, 1974; Weaver
et al., 2004). Much research addressed the generation of
neutralizing antibodies against VEEV since it is classified as
Category B agent by the Centers for Disease Control and
Prevention (CDC). An immune library from human donors
was used as source for selection of mAbs targeting both VEEV
envelope glycoproteins E1 and E2 (Hunt et al., 2010). The
isolated Fabs L1A7 and F5 were neutralizing in vitro, with F5
being 300 times more effective than L1A7. Subsequently, F5 in
full IgG format was employed to generate neutralization-escape
variants of VEEV for epitope mapping purposes. Another study
harnessed an immune macaque library to generate human-like
antibodies. Among these antibodies, scFv-Fc ToR67-3B4 was
protective in mice when administered 6 h post viral challenge
with VEEV Trinidiad strain, allowing 80 to 100% survival after a
challenge with 100-fold LD50. Counterintuitively, scFv-Fc
ToR67-3B4 was able to neutralize other VEEV strains in vitro,
but not Trinidad one. This tests proved that in vitro
neutralization is not mandatory for an antibody to be actually
protective in more complex infection models (Rülker et al.,
2012). A further study described the antibody selection from a
human naïve scFv gene library using complete, active VEEV
particles as target. Specific detection of the VEEV strains TC83,
H12/93, and 230 by the isolated antibodies was verified.
Remarkably, none of the selected scFv phage clones showed
cross-reactivity with Alphavirus species of the Eastern equine
encephalitis virus (EEEV) and Western equine encephalitis virus
(WEEV) antigenic complex or with Chikungunya virus
(CHIKV), making them ideal tools for immunological
detection and diagnostic of Alphavirus species (Kirsch et al.,
2008). From WEEV immunized macaques, two different scFv
antibody gene libraries were constructed. Reformatted as scFv-
Fc, three antibodies originating from these libraries specifically
bound WEEV in ELISA with little or absent cross-reactivity with
other alphaviruses. Additionally, their neutralization potency
was assessed in vitro. This was indeed the first study in whichJuly 2021 | Volume 11 | Article 697876
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About 1 ng/mL of the best antibody (ToR69-3A2) neutralized
50% of 5 x 104 TCID50/mL WEEV (Hülseweh et al., 2014). Four
anti-WEEV antibodies from this study were also tested in an in
vivo WEEV aerosol challenge approach. A dose dependent
protection was measured. Interestingly, not only the best
neutralizing antibody ToR69-3A2 was protective in vivo, but
also the non-neutralizing antibody ToR68-2C3. The mode of
action of the non-neutralizing antibodies cannot be the blocking
of the virus host cell receptor interaction, but protection may
results from complement-mediated lysis, antibody-dependent
cell-mediated lysis of infected cells or opsonization followed by
uptake by phagocytes (Burke et al., 2018). Single domain
antibodies generated against E3E2 of WEEV from a llama
immune library allowed the development of a MagPlex
sandwich immunoassay to detect specifically WEEV and
discriminate from other alphaviruses (Liu et al., 2018).
Influenza viruses are the etiologic agents of seasonal flu, a
worldwide spread disease. In recent years, the “bird flu” (H5N1)
and the pandemic “swine flu” (a variant of H1N1) moved into
the spotlight of public attention and also of research focus, given
the global spread of these variants. Due to many genetic events,
such as e.g. antigenic drift and shift, new influenza variants will
keep occurring in the future and will challenge vaccine and
diagnostic development (Webster and Govorkova, 2014;
Trombetta et al., 2015; Keilman, 2019). Sui et al. (2009)
selected antibodies from a naïve scFv library against the H5
hemagglutinin ectodomain. Hemagglutinin is a trimer and the
extracelluar part consist of a stalk domain and a globular head
domain (Krammer and Palese, 2013). They identified ten
antibodies binding to the trimeric H5, nine of which shared
the same germline framework (VH1-69). These antibodies were
converted into IgG1 and were protective in mice at dose of 10 or
15 mg/kg in both a prophylactic and therapeutic challenge
models, respectively. Very remarkably, some antibodies cross-
neutralized H1, H2, H5, H6, H8, and H9 influenza strains. These
phage display derived antibodies are good candidates for broad-
spectrum influenza immunotherapy (Sui et al., 2009).
Rabies is caused by the rabies virus which infects the central
nervous system, always resulting in fatal disease, before Louis
Pasteur developed the rabies vaccination. The current post-
exposure therapy is based both on vaccination and polyclonal
anti-rabies sera (Goudsmit et al., 2006; Briggs, 2012; Crowcroft
and Thampi, 2015). From two different immune scFv libraries,
147 unique recombinant antibodies were selected against the
rabies glycoprotein (Kramer et al., 2005). The neutralization of
the selected mAbs was tested in vitro using 27 different street
rabies virus isolates and the best neutralizing antibodies were
further investigated in vivo in a hamster rabies (Bakker et al.,
2005). This antibody was further analyzed with another human
antibody, termed CR57, derived by somatic cell hybridization
technique, in combination (Dietzschold et al., 1990), both in in
vitro and in vivo models (Goudsmit et al., 2006). In a clinical
phase 1 study, the safety and efficacy of the mAb cocktail (named
CL184) was tested (Bakker et al., 2008) and subsequently in
phase 2 studies. The antibodies were renamed RafivirumabFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 10(CR57) and Foravirumab (CR4098). The in vivo efficacy in a
hamster model was demonstrated with several rabies isolates
(Franka et al., 2017). The antibody Rabishield, which is not
derived by phage display, has been approved in 2018 (Wang
et al., 2011; Gogtay et al., 2018).
The emergence of new viral species able to leak from their
animal reservoirs and lastly infect the human host has been
described several times in the last decades and has led to either
local epidemics or global pandemics. In this regard, Henipavirus
and Betacoronavirus genera, respectively, are emblematic
examples of zoonotic viral diseases that posed serious threats
to human health. The generation of monoclonal antibodies
through phage display targeting these pathogens has been
mainly investigated towards the development of new
therapeutic agents, even though in the case of SARS-CoV-2
monoclonal antibodies are of foremost interest also for
diagnostic purposes.
Henipaviruses known to be pathogenic to the human host are
Hendra virus (HeV) and Nipah virus (NiV), that caused small
outbreaks in Australia and Malaysia, respectively, first
recognized during 1990 (Weatherman et al., 2018). Bats are the
animal reservoir of these viruses and their transmission to
human beings is either mediated through amplifying hosts, like
pigs or horses, or direct, as documented in NiV Bangladesh 2001
outbreak, through contact between same contaminated food
(Halpin et al., 2011; Weatherman et al., 2018). The infection of
these negative-stranded RNA viruses causes mainly severe
respiratory and neurological symptoms and sequelae with high
mortality rate (Wong and Tan, 2012). The initial contact of these
virus to host cells is mediated by attachment to glycoprotein G
(also known as RBP -Receptor Binding Protein-), that binds the
cellular surface proteins ephrinB2 or ephrinB3 (Bonaparte et al.,
2005; Negrete et al., 2005; Negrete et al., 2006; Navaratnarajah
et al., 2020). The soluble forms of HeV G protein was used to
isolate 17 antibodies from a phage display human Fab naïve
library (Zhu et al., 2006), to date the only report of phage display-
derived anti-NiV/-HeV antibodies. Seven of them were further
investigated and given the 80% sequence similarity between G
proteins of HeV and NiV, some of them resulted in effective
cross-recognition of the two viral species. Fab m102 was further
improved through light chain shuffling, VH randommutagenesis
and IgG1 conversion demonstrating cross-neutralization of both
HeV and NiV and normal serum half-life in ferrets (Zhu et al.,
2008). Further testing of this monoclonal antibody demonstrated
its efficacy in NiV-infected ferrets (Bossart et al., 2009). For
African green monkeys challenged with HeV (Bossart et al.,
2011) and NiV (Geisbert et al., 2014), further evidence suggests
that the therapeutic window in African green monkeys is
different based on the NiV viral strain used (Mire et al., 2016).
Its safety was also recently demonstrated in a Phase I first-in-
human clinical trial (Playford et al., 2020), establishing the
security criteria necessary to proceed to verify its effectiveness
in infected humans in further clinical trials.
The Betacoronavirus genus (single-stranded, positive-sense
RNA viruses) has clearly demonstrated its potential as source of
worldwide health threats during the beginning of the newJuly 2021 | Volume 11 | Article 697876
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from China in late 2002 and late 2019, respectively (Ksiazek et al.,
2003; Lu et al., 2020). Furthermore, smaller outbreaks were
caused by MERS virus in Saudi Arabia, during 2012 as it was
first isolated, and South Korea (2015) (Zaki et al., 2012; Memish
et al., 2020). Unlike the latter virus that keeps circulating in
camelids (Sabir et al., 2016; Kandeil et al., 2019), SARS-CoV and
SARS-CoV-2 originated from bats (Guan et al., 2003; Zhou et al.,
2020) and spread worldwide. If the first SARS-CoV-caused
pandemic was contained by summer 2003 (Cherry, 2004),
COVID-19 pandemics is still lashing the entire world with
recurring waves of infection. Phage display-derived antibodies
are among the multiple approaches quickly deployed to generate
monoclonal antibodies directed to SARS-CoV-2 (Jiang et al.,
2020). In this emergence scenario, anti-nucleocapsid protein
antibodies have been generated through phage display for
diagnostic purposes (Kim et al., 2021). However, the most
efforts have been focused on spike protein, and specifically to
the receptor binding domain (RBD), to directly block the
interaction with the host receptor, aiming to select neutralizing
antibodies for novel therapeutics development. Various formats,
e.g. IgG, Fab, VHH and bispecifics, from mainly human, either
naïve or immune, libraries have been investigated and their
neutralization efficiency was mostly studied in vitro, with
some mAbs that were also tested in animal models (Li et al.,
2020a; Li et al., 2020b; Noy-Porat et al., 2020; Sun Z. et al., 2020;
Zeng et al., 2020; Bertoglio et al., 2021a; Bertoglio et al., 2021b;
Bracken et al., 2021; Ku et al., 2021; Lim et al., 2021). At the
moment of writing, the only anti-SARS-CoV-2 phage-display
derived antibody known to enter clinical trials is STE90-C11
(COR-101) (ClinicalTrials.gov ID: NCT04674566) (Bertoglio
et al., 2021a).
A summary of antibodies generated by phage display against
viruses is presented in Table 2.EUKARYOTIC PATHOGENS
A huge number of antibodies against a broad range of eukaryotic
pathogens has beengenerated byphagedisplay. These recombinant
antibodies are directed against very different parasites, e.g. Taenia
solium (Ribeiro et al., 2013), protozoa, e.g.Cryptosporidiumparvum
(Boulter-Bitzer et al., 2009; Boulter-Bitzer et al., 2010),Plasmodium
falciparum (Roeffen et al., 2001; Lundquist et al., 2006) or
Toxoplasma gondii (Hoe et al., 2005) and fungi such as
Aspergillus fumigatus (Schütte et al., 2009). Beside human
pathogens also veterinary pathogens like Myxobolus rotundus
(Zhang J. Y. et al., 2006) (a fish pathogen) or Babesia gibsoni (a
dog pathogen) (Hirose et al., 2009) and plant pathogens like
Aspergillus niger (Ascione et al., 2004), Fusarium verticilloides
(Hu et al., 2012) or Sclerotinia sclerotiorum (Yang et al., 2009) are
of interest.
The majority of the antibodies to these targets are derived
from human antibody gene libraries, but libraries derived also
from mouse (Fu et al., 1997), chicken (Hu et al., 2012), camel
(Saerens et al., 2008) or macaque (Schütte et al., 2009) have beenFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 11successfully applied to select recombinant antibodies against
eukaryotic pathogens.
Detailed examples for the recombinant antibodies against
several eukaryotic pathogens derived from phage display are
given the following paragraphs.
Allergic bronchopulmonary aspergillosis, saprophytic
aspergilloma, chronic necrotizing aspergillosis and the invasive
aspergillosis which is highly lethal are caused by Aspergillus
fumigatus and are the most important Aspergillus-related
diseases (Broderick et al., 1996; Latgé, 1999). As one possible
consequence of a hematopoietic stem cell transplantation or
solid organ transplantation, an invasive aspergillosis can occur in
these immunocompromised patients (Rüping et al., 2008).
Therefore, an early diagnosis of aspergillosis is crucial for a
successful treatment. The development of a panel of human
antibodies binding to Crf2 was described by Schütte et al. (2009).
The glycosyol hydrolase Crf2 is located in the cell wall of the
growing hyphae. Two kind of antibody gene libraries were used:
a macaque immune library and the human naïve antibody
libraries HAL4/7 (Hust et al., 2011). In addition, two different
antibody selection strategies were performed: A) a panning on
recombinant antigen immobilized on immunostrips. B) a
panning in solution using biotinylated antigen. Six antibodies
were selected from the human naïve libraries and ten from the
macaque immune library. It was observed, that all antibodies
generated by panning in solution bound to conformational
epitopes and the antibodies generated on directly immobilized
Crf2 bound to linear epitopes. Seven antibodies bound to the
native antigen Crf2 on growing hyphae of Aspergillus fumigatus
shown by histopathological immunofluorescence microscopy.
These antibodies didn’t show cross reactions with other
Aspergillus species or Candida albicans. It was shown that anti-
Crf2 antibody MS112-IIB1 was able to neutralize the enzymatic
activity of Crf2, but was not able to reduce the fungal growth in a
rat model of invasive pulmonary aspergillosis (Chauvin
et al., 2019).
Besides the diagnosis in patients, the preventive diagnosis of
Aspergillus pathogens in agricultural products is of importance.
Therefore, Wang et al. developed a nanobody-polyclonal
antibody Sandwich-ELISA (Wang T. et al., 2017). To obtain
polyclonal antibodies and for the construction of a camelid
immune library, rabbits or alpacas, respectively, were
immunized with extracellular antigens and mycelia lysate of A.
flavus, a strain with high levels of aflatoxin. Panning resulted in
one VHH nanobody against the extracellular antigens and two
nanobodies against the mycelia lysate. The developed Sandwich-
ELISA is detecting aflatoxin producing strains of the Aspergillus
spp. in agricultural products before the fungi can produce high
levels of aflatoxin and is therefore suited for early detection.
Malaria is one of the most common mosquito-borne diseases
caused by five different species of Plasmodium, P. falciparum, P.
vivax, P. malariae, P. ovale and P. knowlesi (Cox-Singh et al.,
2008). In humans P. falciparum is responsible for most malaria-
related deaths globally, while P. vivax is the most widespread
parasite (Popovici and Ménard, 2015). The parasites infect
erythrocytes and destroy these cells at the end of theJuly 2021 | Volume 11 | Article 697876





Antibody Origin Application Reference
Australian bat Lyssavirus possibly ABLV -G naive Fab, IgG human ELISA, in vitro neutralization (Weir et al., 2021)
Avian influenza virus
H7N2 (AIV)
complete virus immune VHH camel ELISA (Gong et al., 2016)
Blue tongue virus complete virus semi-
synthetic
scFv chicken ELISA (van Wyngaardt
et al., 2004; Fehrsen
et al., 2005)




human ELISA (Ten Haaf et al.,
2017)
Broad bean mottle virus
(BBMV)
complete virus immune VHH camel ELISA, in vitro neutralization (Ghannam et al.,
2015)
Bovine viral diarrhea virus nonstructural protein 5
(NS5B)
immune VHH camel ELISA, intrabodies (Duan et al., 2020)
Bovine viral diarrhea virus envelope 2 (E2) immune VHH camel ELISA, in vitro neutralization (Li et al., 2017)
Canine Parvovirus VLP of CPV-VP2 immune scFv chicken ELISA, WB, ICA, virus suppression
assay





scFv human ELISA, WB (Ziegler et al., 1995)
Chikungunya virus
(CHIKV)
VLPs immune VHH llama ELISA, in vitro neutralization (Liu et al., 2019)
Chikungunya virus
(CHIKV)
VLPs with E1 and E2 immune Fab, IgG human ELISA, in vitro neutralization, in vivo
protection
(Fong et al., 2014)




Dengue nonstructural protein 5 (NS5) naïve Fab human ELISA, WB, dot blot, (Zhao et al., 2014)
Dengue Dengue virus envelope
protein




ELISA, WB, IHC (Moreland et al.,
2012)




VHH llama ELISA, lateral flow
immunochromatograpic assay
(Fatima et al., 2014)
Dengue n.d. immune Fab, IgG chimpanzee ELISA, immunoprecipitation, in vitro
neutralization
(Men et al., 2004)
Dengue NS1 immune VHH llama ELISA (MagPlex assay) (Shriver-Lake et al.,
2018)
Dengue NS1 naïve scFv, Fab human ELISA, IF (Lebani et al., 2017)
Dengue NS1 naïve scFv human ELISA, IF, in vitro neutralization (Poungpair et al.,
2014)
Dengue DENV-2 RdRp naive scFv human ELISA, WB, in vitro inhibition (Tunghirun et al.,
2020)
Duck hepatitis A virus VP1 immune VHH camel ELISA, IF, dot-blot (Xue et al., 2019)









Ebola nucleoprotein synthetic scFv, IgG human ELISA, WB (Shingarova et al.,
2007)
Ebola (Zaire) viral matrix protein VP40,
nucleoprotein
immune scFv, IgNAR mice, shark ELISA, WB (Goodchild et al.,
2011)
Ebola (Zaire) VP35 semi-
synthetic
scFv human ELISA, WB, intrabody (Flego et al., 2019)
Ebola (Sudan) glycoprotein (GP) immune scFv, scFv-
Fc
macaque ELISA, in vitro neutralization, in vivo
protection
(Froude et al., 2018;
Herbert et al., 2020)
Ebola (Zaire) glycoprotein (GP) immune VHH llama ELISA (Liu et al., 2017)




human ELISA, IF, WB (Seesuay et al.,
2018)
Ectromelia virus (ECTV) ECTV, variola virus, vaccinia
virus, cow pox virus
immune scFv human ELISA, in vitro neutralization, WB (Khlusevich et al.,
2018)
Enterovirus 71 (EV71) virion protein 2 (VP2) naïve scFv mice ELISA, WB (Thanongsaksrikul
et al., 2018)
Enterovirus 71 inactivated EV71 virions immune Fab human ELISA, in vitro neutralization (Chen et al., 2017)
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VP4 immune scFv, IgG mice WB, in vitro neutralization (Zhang et al., 2016)
Enterovirus 71 VP4 naïve scFv human ELISA, WB, IF, in vitro neutralization (Phanthong et al.,
2020)
Epstein-Barr virus LMP1 naïve Fab human ELISA, WB, IF, FACS, in vitro
inhibition
(Zhang et al., 2013)
Foot-and-mouth disease
virus (FMDV)
3ABC immune scFv chicken ELISA, WB (Foord et al., 2007)
Foot-and-mouth disease
virus




VP2 capsid protein immune scFv mice ELISA (Salem et al., 2019)
Foot-and-mouth disease
virus




coat protein immune scFv mice ELISA (Orecchia et al.,
2008)
Grapevine virus B virus particles semi-
synthetic






scFv mouse ELISA, WB, IHC (Liu H. et al., 2014)
Hantavirus nucleoprotein immune VHH llama ELISA, WB (Pereira et al., 2014)
Hantavirus virus particles immune Fab human IF, WB (Koch et al., 2003)
HCMV gycoprotein B and H immune scFv human ELISA, in vitro neutralization (Nejatollahi et al.,
2002)
HCMV Gp55 immune scFv human ELISA, in vitro neutralization (Moazen et al., 2016)
Hendra and Nipah virus attachment envelope
glycoprotein G
naïve Fab, IgG human ELISA, immunoprecipitation, WB, in
vitro neutralization IF, in vivo
neutralization
(Zhu et al., 2006;
Zhu et al., 2008)
Hepatitis A Hepatitis A Capsid immune Fab, IgG chimpanzee ELISA, in vitro neutralization (Schofield et al.,
2002)
Hepatitis A HBsAG naïve scFv human ELISA (Zhang J.-L et al.,
2006)
Hepatitis C NS5B naïve scFv human ELISA, IF, in vitro neutralization (Thueng-in et al.,
2014)
Hepatitis C core, E1, E2 immune scFv human ELISA (Chan et al., 1996)
Hepatitis C core protein immune Fab human ELISA (Barban et al., 2000)
Hepatitis C E2 glycoprotein immune Fab human ELISA (Burioni et al., 2001)
Hepatitis C NS5A naïve scFv
(transbodies)
human ELISA, WB, IF, in vitro neutralization (Glab-Ampai et al.,
2017)
Hepatitis C NS3/4A naïve scFv
(transbodies)
human ELISA, IF, in vitro neutralization (Jittavisutthikul et al.,
2016)
Hepatitis E ORF2 protein immune Fab chimpanzee ELISA, WB (Schofield et al.,
2000)
Herpes simplex virus HSV1, -2 lysate immune Fab human in vitro inhibition, immuno
precipitaton
(Burioni et al., 1994)
Herpes simplex virus glycoprotein gD, gB presumably
immune
Fab human ELISA, immuno precipitation (Sanna et al., 1995)
Herpes simplex virus virus lysate? immune Fab human ELISA, IF (Cattani et al., 1997)
HIV-1 Integrase immune scFv rabbit ELISA, WB, IF, in vitro neutralization (da Silva et al., 2012)
HIV-1 gp140 immune scFv, scFv-
Fc
human ELISA, WB, immunoprecipitation, in
vitro neutralization
(Trott et al., 2014)
HIV-1 gp140 immune Fab, IgG human ELISA, WB, in vitro neutralization (Choudhry et al.,
2007)
HIV-1 gp140 immune VHH llama ELISA, in vitro neutralization (Strokappe et al.,
2012)
HIV-1 gp120 synthetic CH2 domain human ELISA, in vitro neutralization (Xiao et al., 2009)
HIV-1 p24 immune scFv mouse ELISA (Mohammadzadeh
et al., 2014)
HIV-1 gp41 synthetic Fab human WB, in vitro neutralization (Gustchina et al.,
2007)
HIV-1 gp41 naïve scFv human ELISA, in vitro neutralization (Miller et al., 2005)
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Antibody Origin Application Reference
HIV-1 gp120 immune Fab human ELISA, in vitro neutralization, IF (Sun et al., 2017)
HIV-1 gp140 immune VHH camel ELISA, in vitro neutralization (Koch et al., 2017)
HIV-1 gp140 trimer immune scFv human ELISA, in vitro neutralization (He et al., 2017)
HIV-1 RSC3 core protein immune scFv human ELISA, in vitro neutralization (Kumar et al., 2017)
HIV-2 gp125 protein immune Fab human ELISA, in vitro neutralization (Björling et al., 1999)
Human metapneumovirus F ectodomain presumably
immune
Fab human ELISA, IF, in vitro neutralization, in
vivo protection
(Williams et al., 2007)
Influenza A (IAV) HA (stem region) semi-
synthetic
scFv human(IGHV1-69) ELISA, in vitro neutralization (Avnir et al., 2014)
Influenza A HA ectodomain naïve scFv human ELISA, Flow cytometry,
immunoprecipitation, in vitro
neutralization, in vivo protection
(Sui et al., 2009)
Influenza A (H2N2) HA (stem region) presumably
immune
Fab human ELISA, in vitro neutralization (Wyrzucki et al.,
2014)
Influenza A HA2 semi-
synthetic
scFv human ELISA, WB, in vitro neutralization (Li et al., 2016)
Influenza A (H1N1) HA immune scFv mice ELISA (Rajput et al., 2015)
Influenza A (H1N1/H5N1) HA immune VHH,
bivalent
VHH
alpaca ELISA, in vitro neutralization (Hufton et al., 2014)
Influenza A (H5N1) HA semi-
synthetic
scFv human ELISA (Wu et al., 2014)




Influenza A (H5N1) HA immune Fab chicken IF, in vitro neutralization, WB (Pitaksajjakul et al.,
2010)
Influenza A (H5N1) nucleoprotein (NP) immune scFv mice ELISA, WB, in vitro inhibition (Sengupta et al.,
2014)
Influenza A (H5N1) HAcleavage site immune Fab mice ELISA, IF (Dong et al., 2013)
Influenza A (H5N1) NS1 naïve scFv human ELISA, in vitro neutralization, IF (Yodsheewan et al.,
2013)
Influenza A (H5N1) complete inactivated virus immune VHH camel ELISA (Zhu et al., 2014)




scFv human ELISA (Vashisht et al.,
2019)
Influenza A M2-cytoplasmatic domain naïve scFvscFv-Fc human WB, IHC (Velappan et al.,
2020)
Influenza B HA immune VHH alpaca ELISA (Ramage et al.,
2019)
Influenza B whole virus immune Fab human ELISA, WB, IF, in vitro neutralization (Hirano et al., 2018)
Japanese encephalitis
virus
domains I,II,III of envelope
protein
immune Fab, IgG chimpanzee ELISA, immunoprecipitation, in vitro









Marburg virus glycoprotein (GP) immune scFv, scFv-
Fc
macaque WB, in vitro neutralization, in vivo
protection
(Froude et al., 2017)
Marburg virus VP35 synthetic Fab human ELISA (Amatya et al., 2019)
Measles virus virus lysate immune
(Puumala
hantavirus)
Fab human ELISA, in vitro neutralization (de Carvalho Nicacio
et al., 2002)
MERS S2 domain synthetic Fab, IgG human ELISA, IF, sandwich ELISA (Kim et al., 2019)
MERS nucleoprotein (NP) naïve scFv human ELISA (Lim et al., 2019)
Norovirus Norovirus VLPs semi-
synthetic
scFv human ELISA, WB (Huang et al., 2014)




scFv human ELISA, dot-blot (Hurwitz et al., 2017)
Norovirus VLPs with VP1 and VP2 immune VHH llama ELISA, WB, in vitro inhibition, IF (Garaicoechea et al.,
2015)
Norovirus VLPs naïve scFv human ELISA, in vitro inhibition (Higo-Moriguchi
et al., 2014)
Norwalk virus VLPs immune Fab, IgG chimpanzee ELISA, FACS, IF, in vitro inhibition (Chen et al., 2013)
Paramyxovirus glycoproteins F and HN synthetic Fab, sAb human ELISA, in vitro neutralization,
immunoprecipitation
(Welch et al., 2014)
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Antibody Origin Application Reference
Plum pox virus NIa protease semi-
synthetic
scFv human WB, dotblot (Hust et al., 2002)
Poliovirus capsid proteins VP1 and VP3 immune Fab, IgG chimpanzee ELISA, in vitro neutralization, in vivo
protection
(Chen et al., 2011)
Polyomavirus JC (JCV) VLPs synthetic Fab, IgG human ELISA (Chen et al., 2015)
Porcine circovirus type 2 Cap protein immune VHH camel ELISA (Mu et al., 2021)
Porcine epidemic diarrhea
virus
PEDV S1 domain of spike
protein
immune VHH camel ELISA, IF (Bao et al., 2019)
Porcine epidemic diarrhea
virus
nucleocapsid (N) protein immune VHH camel ELISA (Ma et al., 2019)
Porcine epidemic diarrhea
virus












Nsp9 iummune VHH camel ELISA, IF, in vitro inhibition (Liu et al., 2015)
Puumala hantavirus N protein, G2 protein immune Fab human ELISA (Salonen et al.,
1998)
Puumala hantavirus gycoprotein G2 immune Fab human ELISA, IF, in vitro neutralization (de Carvalho Nicacio
et al., 2000)
Rabies virus glycoprotein semi-
synthetic
scFvscFv-Fc human ELISA, WB, in vitro neutralization (Ray et al., 2001)
Rabies virus glycoprotein immune scFv, IgG human ELISA, flow cytometry, in vitro
neutralization
(Bakker et al., 2005;
Kramer et al., 2005)
Rabies virus n.d. immune Fab human ELISA (Houimel, 2014)
Rabies virus glycoprotein (antigenic site II) immune Fab, IgG human ELISA, immunostaining, WB, in
vitro neutralization, in vivo
protection
(Sun et al., 2012)
Rabies virus inactivated RABV naïve VHH, VHH
pentamer
lama ELISA, in vitro neutralization, in vivo
protection
(Boruah et al., 2013)
Respiratory syncytial virus
(RSV)
F protein synthetic Fab, IgG human ELISA, in vitro neutralization (Chen et al., 2016)
Rotavirus NSP4 semi-
synthetic




scFv human ELISA, WB, in vitro inhibition (Monedero et al.,
2004)
SARS-CoV S1 domain of spike protein naïve scFv human ELISA, in vitro neutralization (Sui et al., 2004)
SARS-CoV S protein immune Fab, IgG human ELISA, IF, immuno blot, in vitro
neutralization
(Liang et al., 2005)
SARS-CoV S protein immune scFv chicken ELISA, IF (Lee et al., 2007)
SARS-CoV-2 S protein (RBD) naïve scFv, scFv-
Fc, IgG




SARS-CoV-2 S protein (RBD) immune scFv, scFv-
Fc, IgG
human ELISA, in vitro inhibition, in vitro
neutralization, in vivo protection
(Bertoglio et al.,
2021a)
SARS-CoV-2 S protein (RBD) naïve scFv, scFv-
Fc
human ELISA, in vitro neutralization (Noy-Porat et al.,
2020)
SARS-CoV-2 S protein (RBD) synthetic VHH humanized in vitro neutralization (Chi et al., 2020)
SARS-CoV-2 S protein (RBD) synthetic Fab human ELISA, in vitro neutralization (Zeng et al., 2020)
SARS-CoV-2 S protein (RBD) immune VHH, VHH-
Fc
alpaca ELISA, in vitro inhibition, IF (Ma et al., 2021)




human ELISA, WB (Parray et al., 2020)
SARS-CoV-2 S protein (RBD) immune VH human ELISA, FACS, in vitro neutralization (Sun et al., 2020)
SARS-CoV-2 S protein (RBD) synthetic VH human ELISA, in vitro neutralization (Bracken et al.,
2021)
SARS-CoV-2 S protein (RBD) synthetic Fab,
bispecific
Fab+VH
human in vitro neutralization (Lim et al., 2021)
SARS-CoV-2 S protein (RBD) naïve scFv human ELISA, in vitro neutralization, in vitro
inhibition, in vivo protection
(Ku et al., 2021)
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Antibody Origin Application Reference
SARS-CoV-2 RBD immune Fab, IgG human ELISA, in vitro neutralization assay,
in vivo protection,
(Zhou et al., 2021)
SARS-CoV-2 RBD semi-
synthetic
Fab human ELISA, in vitro neutralization (Slezak and
Kossiakoff, 2021)
SARS-CoV-2 RBD immune VHH alpaca ELISA, in vitro inhibition, in vitro
neutralization
(Gai et al., 2021)
SARS-CoV-2 NP immune scFv, scFv-
Fc
chicken ELISA, dotblot, lateral flow strip
assay
(Kim et al., 2021)
SARS-CoV-2 NP immune Fab, IgG human ELISA, WB (Zhang et al., 2020)
Simian immunodeficiency
virus (SIV)




gp120/gp140 immune scFv, scFv-
Fc
rhesus macaque WB, in vitro neutralization (Ita et al., 2017)
Sin Nombre Virus SNV-N naïve scFv human ELISA, WB, dot-blot (Velappan et al.,
2007)
Swine Influenza Virus SIV-NP immune VHH camel ELISA, WB (Du et al., 2019)
Transmissible
gastroenteritis virus
TGEV whole virus immune scFv pig in vitro neutralization, IF, WB (Zhang et al., 2019b




Vaccinia B5 envelope protein immune Fab, IgG chimpanzee ELISA, in vitro neutralization, in vivo
protection
(Chen et al., 2006)
Vaccinia virus virus particles immune scFv, IgG human inhibition ELISA, in vitro
neutralization
(Shin et al., 2019)
Vaccinia virus inactivated virus particles, L1 immune VHH llama MAGPIX assay, FACS (Walper et al., 2014)
VEEV virus particles immune scFv mice ELISA (Duggan et al., 2001
VEEV E1/E2 naïve scFv, scFv-
Fc
human ELISA, WB, IHC (Kirsch et al., 2008)
VEEV E1 immune scFv, scFv-
Fc
macaque ELISA, WB, IHC, in vitro
neutralization, in vivo protection
(Rülker et al., 2012)
WEEV virus particles immune scFv, scFv-
Fc
macaque ELISA, IHC, in vitro neutralization, in
vivo protection
(Hülseweh et al.,
2014; Burke et al.,
2018)
WEEV E2/E3E2 immune VHH llama ELISA (MagPlex assay) (Liu et al., 2018)
West nile virus domain I and II of WNV
envelope protein
naïve scFv human ELISA, in vitro neutralization, in vivo
protection
(Gould et al., 2005)
West nile virus domain IIII of WNV envelope
protein
immune Fab human ELISA, IF, in vitro neutralization, in
vivo protection (failed)
(Duan et al., 2009)
West nile virus envelope (E) naïve scFv, scFv-
Fc
human ELISA, WB, in vitro neutralization (Rizzo et al., 2020)
White spot syndrome
virus
virus particles immune scFv mice ELISA, in vitro neutralization (Yuan et al., 2006)
Yellow fever virus domain II of envelope protein immune scFv, IgG human ELISA,WB, immunoprecipitation, in
vitro neutralization, in vivo
protection
(Daffis et al., 2005;
Lu et al., 2019)
Zika virus envelope domain III naïve Fab human in vitro neutralization, in vivo
protection
(Wu et al., 2017)
Zika virus envelope (E) immune scFv chicken ELISA, WB, FACS, in vitro inhibition (Mwale et al., 2020)
Zika virus NS1 Immune VHH llama ELISA (Delfin-Riela et al.,
2020)ELISA, enzyme linked immunosorbent assays; HA, hemagglutinin; HCMV, Human cytomegalovirus; HIV, Human immunodeficiency virus; IF, immuno fluorescence microscopy; IHC
immunohistochemistry; RABV, Rabies virus; MERS, Middle East Respiratory Syndrome Coronavirus; SARS, Severe acute respiratory syndrome; VLP, virus like particle; VEEV, Venezuelan
equine encephalitis virus; WB, western blot; WEEV, Western equine encephalitis virus.
Roth et al. Recombinant Antibodies Against Infectious Diseasesreplication cycle. In tropical and subtropical countries there are
approximately 3.2 billion people at risk of malaria (Tolle, 2009;
Muerhoff et al., 2010). Because the life cycle of Plasmodium
consists of different development stages, different targets of
P. falciparum were addressed for antibody generation. Roeffen
et al. (2001) targeted Pfs48/45, a surface protein of P. falciparum
which is expressed during macrogamete and zygote stages. Pfs48/
45 is also a potential vaccine candidate because transmission-
blocking anti-Pfs48/45 antibodies taken up by the mosquito
during the blood meal and block the oocyte development
within the mosquito’s intestinal tract (Rener et al., 1983;
Kumar and Carter, 1984; Vermeulen et al., 1985). To generate
anti-Pfs48/45 antibodies, two human immune libraries were
constructed from B-lymphocytes derived from P. falciparum
patients with transmission-blocking immunity.
The antibody selection was performed in immunotubes with
immobilized extract of gametocytes. To specifically generate
antibodies against Pfs48/45, the scFv-phage were eluted by
competition using a cocktail of four rat monoclonal Abs
recognizing distinct epitopes on Pfs48/45 (epitopes I, IIb, III
and V). Remarkably, one epitope, the epitope III of Pfs48/45, was
bound by all of the generated antibodies. Human monoclonal
antibodies against the Block 2 region of Plasmodium falciparum
merozoite surface protein-1 (PfMSP-1) were isolated by phage
display from a scFv immune library of a malaria patient (Sowa
et al., 2001). A Fab-immune library was constructed using
lymphocytes of thirteen adults with acquired immunity to
malaria. Finally, three Fabs (RAM1, 2 and 3) were isolated by
panning on the merozite surface protein 3 (MSP-3194-257)
(Lundquist et al., 2006). This protein is involved in the binding
of heme and the antibodies promote the depletion of
Plasmodium by monocytes (Oeuvray et al., 1994; Imam et al.,
2014). Therefore, the N-terminal fragment of MSP-3 was also
tested in clinical vaccines trials (Audran et al., 2005). Binding of
the antibodies to native parasite protein was demonstrated for all
three antibodies in immunofluorescence microscopy and
immunoblot. The native MSP-3 was bound by RAM1 and
RAM2 in fixed and permeabilized cells. The anti-MSP-3
antibodies were produced as IgG1 and also in the IgG3 format
and tested in an antibody-dependent cellular inhibition assay
(ADCI). The IgG3 format of RAM1 showed an inhibition rate
that is comparable to affinity-purified polyclonal anti-MSP-3211-
237 antibodies derived from human immune donors. In contrast,
the IgG1 format also showed a lower inhibition in this assay
compared to IgG3 (Lundquist et al., 2006). In 2021, Seidel-
Greven et al. (2021) presented a monoclonal antibody directed
against AMA-1, the apical membrane antigen 1. As anti-AMA-1
antibodies show a high prevalence in immune individuals it is
not only an interesting target for therapeutics but also one of the
major blood-stage vaccine candidates. A human malaria Fab-
immune library was used to select antibodies against a set of
three AMA-1 variants. To improve the affinity and functional
activity a light chain shuffling was performed. After subcloning
to IgG1/ϰ, affinity and competition studies were performed by
surface plasmon resonance (SPR) spectroscopy. In addition to an
immunofluorescence assay (IFA), the antibodies were tested inFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 17an in vitro growth assay. Here, all antibodies were able to inhibit
the growth of four different P. falciparum strains including 3D7.
Therefore, those antibodies might be the fundament for the
development of an antibody cocktail for therapeutic or
prophylactic anti-malaria approaches. In 2014, Leow et al.
(2014) aimed to find new antibodies with higher thermal
stability. As degradation of antibodies due to high
temperatures in the endemic countries are affecting the shelf
life of malaria rapid diagnostic tests (RDTs). Therefore, they
performed a panning with a naïve human scFv library on the
histidine-rich protein 2 (PfHRP2) of P. falciparum. PfHRP2 is a
biomarker used in most RDTs, as it is abundantly expressed in
erythrocytes across all asexual stages and is released during the
rupture of the red blood cells. Additionally, it remains detectable
in the blood for up to 28 days. Isolated binders were cloned into
the IgG format, produced in CHO cells and were compared to a
commercial antibody. The selected antibodies showed
comparable specificity and sensitivity, with higher thermal
stability, making them candidates for a field test in a prototype
test kit. To further cope with the degradation issues, Leow et al.
(2018) created a shark immune library consisting of VNARs. The
variable domain of the shark antibodies is known to have a high
thermal stability and therefore is a potential alternative for the
RDTs. A wobbegong shark (Orectolobus ornatus) was
immunized with different malaria proteins (PfHRP2, PfpLDH
and Pvaldolase), used for the construction of a VNAR single
domain library and antibodies were selected against all three
proteins. Pvaldolase and pLDH are used for diagnosis of non P.
falciparum malaria infections and P. vivax infections. Specificity
and sensitivity of the anti-PfHRP2 antibodies were demonstrated
by Sandwich-ELISA and dot blot analysis. Further engineering
could lead to a new generation of RDTs.
Table 3 gives an overview of antibodies generated by phage
display against eukaryotic pathogens.ANTIBODIES AGAINST TOXINS
The Center for Disease Control and Prevention (CDC) classifies
several bacterial toxins and/or the pathogens producing these
toxins as category A or B agent as they are a high risk to national
security and public health (see: https://www.niaid.nih.gov/
research/emerging-infectious-diseases-pathogens). Thus, these
toxins are a relevant target for development of diagnostics and
therapeutics (Froude et al., 2011). Here, antibody phage display
technology is a powerful tool to select diagnostic as well as
neutralizing antibodies against complete active toxins or certain
domains by using human naïve antibody libraries with high
diversity (Indrawattana et al., 2010; Amaro et al., 2011; Neri
et al., 2011). The aim of such neutralizing antibodies is in most
cases to block the interaction of the toxin to its cellular target, by
binding to the cell binding domain of the toxin. However,
neutralization of the toxicity is also possible by antibodies
directed against other domains like the translocation domain
or the enzymatic domain (Fühner et al., 2018; Wenzel et al.,
2020a). Immunization of animals with toxoids, non-toxicJuly 2021 | Volume 11 | Article 697876
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Alexandrium minutum Whole cell/surface epitopes naïve nanobody/
fluobody
lama IF (Mazzega et al., 2019)
Aspergillus flavus extracellular antigens &
mycelia lysate
immune nanobody alpaca ELISA (sandwich), WB (Wang T. et al., 2017)






ELISA, IF (Schütte et al., 2009)
Aspergillus niger glucose oxidase semi-
synthetic
scFv human ELISA (Ascione et al., 2004)
Babesia gibsoni P50 semi-
synthetic
scFv human ELISA, IF (Hirose et al., 2009)
Balamuthia mandrillaris whole cell/surface antigens naïve scFv human ELISA, IHC (Siddiqui et al., 2016)
Botrytis cinerea fungal glucosylceramides
(fGlcCer)
immune VHH llama ELISA, in vitro activity assay (De Coninck et al., 2017)
Brugia malayi BmR1 naïve,
immune
scFv human ELISA, WB (Rahumatullah et al., 2017)
Brugia malayi BmSXP immune scFv human ELISA, WB (Rahumatullah et al., 2015;
Rahumatullah et al., 2019)
Candida albicans Als3p and other naïve scFv human ELISA, IF, WB, in vitro
neutralization
(Haidaris et al., 2001; Bliss et al.,
2003; Laforce-Nesbitt et al., 2008)
Cryptosporidium parvum P23 semi-
synthetic
scFv human ELISA (Boulter-Bitzer et al., 2009)
Cryptosporidium parvum S16 semi-
synthetic
scFv human ELISA (Boulter-Bitzer et al., 2010)
Echinococcus granulosus AgB immune scFv human ELISA (Rahumatullah et al., 2020)
Fasciola hepaticum cathepsin L1 immune scFv rat ELISA, WB (Norbury et al., 2019a)
Fasciola hepaticum cathepsin B2 naïve scFv mice ELISA, WB (Norbury et al., 2019b)
Fusarium oxysporum cell wall-bound protein immune scFv chicken ELISA, IF, scFv-AFP (anti-
fungal peptide) fusion protein
(Peschen et al., 2004)
Fusarium verticillioides cell wall-bound proteins immune scFv chicken ELISA, IF (Hu et al., 2012)




chicken ELISA, IF, WB (Hu et al., 2013)
Haemonchus contortus excretory/secretory (ES)
products
immune scAb sheep IF, transepithelial resistance
assay
(Rehman et al., 2016)
Leishmania infantum b-tubulin naïve scFv human ELISA, WB (Costa et al., 2019)
Myxobolus rotundus spore protein immune scFv mice ELISA, in vitro neutralization (Zhang J. Y. et al., 2006)
Neospora caninum rNcSRS2 immune Fab mice ELISA, IF (Dong et al., 2014)
Onchocerca volvulus Ov16 synthetic Fab, IgG human ELISA, rapid diagnostic
platform
(Golden et al., 2016)
Paranosema locustae alpha-/beta-hydrolase immune scFv, mini
antibody
mice WB, IF (Dolgikh et al., 2017)
Plasmodium chabaudi AMA-1 immune scFv mice ELISA, WB (Fu et al., 1997)
Plasmodium falciparum MSP-1 immune scFv human ELISA, IF (Sowa et al., 2001)
Plasmodium falciparum MSP-3 immune Fab,IgG human ELISA, IF, WB, FACS (Lundquist et al., 2006)
Plasmodium falciparum Pfs48/45 immune scFv human ELISA, WB (Roeffen et al., 2001)




VNAR shark ELISA, dot blot (Leow et al., 2018)
Plasmodium falciparum PfHRP2 naïve scFv human ELISA (sandwich), WB, dot
blot
(Leow et al., 2014)
Plasmodium falciparum AMA-1 immune Fab, IgG human ELISA, IF, in vitro inhibition (Seidel-Greven et al., 2021)
Plasmodium yoelii MSP1 immune scFv mice ELISA, WB, in vivo
protection
(Vukovic et al., 2002)
Schisostoma japonicum Schisostoma japonicum
cercariaeschistosomules
immune scFv buffalo IF, WB, ELISA, protein
microarray
(Hosking et al., 2015a; Hosking
et al., 2015b)
Schizophyllum commune beta-(1,6)-Branched beta-
(1,3)-D-Glucan Schizophyllan
immune scFv mice ELISA (Josewski et al., 2017)
Strongyloides stercoralis rNIE immune scFv human ELISA, WB (Rahumatullah et al., 2021)





scFv human ELISA, IF (Levenhagen et al., 2015)
Taenia solium TS14 immune VHH camel ELISA, WB (Deckers et al., 2009)
Taenia solium T. solium metacestodes,
peptides
naïve scFv human ELISA, IF (Ribeiro et al., 2013)
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high-affinity antibodies with immune antibody libraries.
Especially well-suited for the construction of such immune
antibody libraries are macaques as there V-genes are very
similar to their human counterparts (Chassagne et al., 2004;
Pelat et al., 2007; Pelat et al., 2009; Rülker et al., 2012; Miethe
et al., 2014; Miethe et al., 2015). Alternatively, also B-cells from
vaccinated humans can be used in cases where an approved
vaccine is available (Wenzel et al., 2020a).
So far, neutralizing antibodies have been successfully selected
against several toxins, classified as category A agents, such as
botulinum toxins causing botulism from Clostridium botulinum
(Amersdorfer et al., 2002; Conway et al., 2010; Hu et al., 2010;
Miethe et al., 2014) and anthrax toxins from Bacillus anthracis
(Pelat et al., 2007) and also against different category B agents,
such as staphylococcal enterotoxin B (Larkin et al., 2010; Chen
et al., 2019). We focused on toxins produced by microorganisms
and did not include e.g. plant toxins like the potential biowarfare
agent ricin (Pelat et al., 2009) or anti-venom, e.g. anti-snake
toxin, antibodies (Laustsen et al., 2018).
One microorganism with the high-risk to be potential used as
a bioweapon is the Gram-positive, anaerobic, spore-forming
bacterium Clostridium botulinum and other Clostridium spp.
that produce the most toxic substances known: eight different
serotypes (A-H) of botulinum neurotoxin (BoNT). Five of these
serotypes (A, B, E, rarely F, only one case of H) cause human
botulism. Human botulism results in flaccid muscle paralysis
what requires intensive hospital care and passive immunization
(Arnon et al., 2001; Barash and Arnon, 2014). The most toxic
substance is serotype A with a LD50 of about 1 ng/kg by
intravenous route, about 10 ng/kg by the pulmonary route and
about 1 µg/kg for the oral route (Dembek et al., 2007). BoNTs
consist of a 50 kDa light chain and a 100 kDa heavy chain linked
by a disulfide bound. Receptor-mediated endocytosis followed by
translocation of the light chain across the membrane into the
neuronal cytosol is facilitated by two functional domains (Hc and
Hn) of the heavy chain. The light chain contains the catalytic
domain responsible for the BoNT toxicity. Currently botulism is
treated by the application of anti-botulism immunoglobulins,
such equine serum or the human serum BabyBIG against type A
and B. Yet the availability of BabyBIG is limited while equine
serum may cause serum sickness and hypersensitivity. Here,
antibody phage display technology has been used to generateFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 19toxin-neutralizing antibodies against each serotype. One single
domain antibodies (VHH) was selected by phage display of a
llama immunized with a cocktail of seven BoNT toxoids (A-F)
(Conway et al., 2010; Shriver-Lake et al., 2017). Other VHH have
been isolated from immunized alpacas and were produced as
VHH-Fc fusion. These antibodies were protective against LD50
BoNT/A and showed protection over 14 days after antibody
administration (Godakova et al., 2019). Furthermore, a human
antibody gene library could be generated after in vitro
immunization with BoNT/A (Hu et al., 2010). Macaque
immune libraries were used to isolate neutralizing scFv against
the light chains (Lc) and heavy chains (Hc) of BoNT/A, -B and
-E with nM affinities against by the EU AntibotABE project
(Chahboun et al., 2011; Miethe et al., 2014; Avril et al., 2015;
Rasetti-Escargueil et al., 2015). These antibodies were germline-
humanized and the in vivo protection was analyzed in non-lethal
and lethal mice challenge experiments. For BoNT/A and BoNT/
B neutralizing anti-Lc and anti-Hc antibody showed only limited
protection, but the combination of anti-LC and anti-HC
antibodies showed a synergistic effect and 100% protection
when using 2.5 µg/mice (Miethe et al., 2016). Interestingly, no
neutralizing antibodies against the Hc of BoNT/E were selected,
but the neutralizing anti-Lc antibody alone showed full in vivo
protection using only 2.5 ng IgG/mice (Derman et al., 2016).
Another serious infectious disease is anthrax caused by toxins
of Bacillus anthracis, an aerobic, Gram-positive, spore-forming
bacterium found in soils all over the world. Bacillus anthracis
secretes the lethal toxin (LT) consisting of the lethal factor (LF)
and the protective antigen (PA); while the edema toxin (ET) is
formed by the edema factor (EF) and PA (Liu S. et al., 2014). In
the pathogenesis of anthrax only LT is essential (Inglesby et al.,
2002). Production and dissemination as aerosol of anthrax toxin
is easily possible highlighting its potential as a bioweapon (Oncü
et al., 2003). Vaccines are currently based on the subunit PA to
induce the generation of neutralizing antibodies. For treatment,
commercial monoclonal antibodies against PA, such as
Raxibacumab, are commonly used in combination with
antibiotics (Kummerfeldt, 2014). Raxibacumab was approved
by the FDA in 2012 to treat inhalational anthrax. However, as PA
could be mutated and modified to escape neutralizing PA
antibodies while still maintaining biological activity, the use of
anti-PA antibodies alone presents a security issue. An alternative
and additional target presents the LF domain. Such an antibodyTABLE 3 | Continued







Trypanosoma cruzi P2ß immune scFv human ELISA, WB (Grippo et al., 2011)




different surface proteins immune VHH alpaca WB, IHC (Obishakin et al., 2014)
Toxoplasma gondii TgMIC2 immune scFv mice ELISA, WB (Hoe et al., 2005)
Toxoplasma gondii tachyzoites immune scFv mice ELISA, WB, IF, in vitro
invasion, attachment assays
(Lim et al., 2018)JulyELISA, enzyme linked immunosorbent assays; IHC, immuno histo chemistry; IF, immuno fluorescence microscopy; FACS, fluorescence-activated cell sorting; WB, Western blot.2021 | Volume 11 | Article 697876
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via antibody phage display technology (Pelat et al., 2007). Also a
synergistic effect of the combination of an anti-PA together with
an anti-LF antibody is to be expected and would improve the
efficacy of the therapy.
Staphylococcal enterotoxin B (SEB) from Staphylococcus
aureus is an example for a bacterial toxin classified as category
B agent, that could potentially cause foodborne illness.
Staphylococcus aureus produces in total twenty-one types of
staphylococcal enterotoxins leading to food poisoning with
abdominal cramps, diarrhea and vomiting (Thomas et al.,
2006; Ono et al., 2008). The most potent toxin secreted by S.
aureus is SEB, a single 28 kDa polypeptide. As a superantigen, it
stimulates T cells leading to an overproduction of cytokines,
resulting in fever, hypertension and in some cases death. Phage
display was employed to identify the epitope of a SEB specific
monoclonal antibody using a peptide phage library (Urushibata
et al., 2010) and to generate recombinant antibodies from a
murine immune library (Singh et al., 2010). Additionally,
synthetic human Fab libraries was used to generate human
monoclonal antibodies blocking SEB binding to MHC-II
(Larkin et al., 2010) and neutralizing SEB in vitro and in vivo
(Chen et al., 2019). In contrast to the therapeutic use, phage
display was applied to generate nanobodies against SEB from
camel immune and naive libraries useful as a diagnostic tool.
These nanobodies were either directly coupled with alkaline
phosphatase in a sandwich-ELISA (Sun T. et al., 2020), or used
for western-blot and ELISA in an indirect detection system
(Zanganeh et al., 2019).
In the late 1970ies, Clostridioides difficile was discovered as the
pathogen causing antibiotic treatment associated diarrhea (CDAD)
(Bartlett et al., 1978). Only strains expressing at least Toxin B
(TcdB) mostly together with Toxin A (TcdA) result in disease and
typical symptoms of CDAD (Bartlett et al., 1978). Only strains
expressing at least Toxin B (TcdB), mostly together with Toxin A
(TcdA), result in disease and typical symptoms of CDAD
(Natarajan et al., 2013). TcdA and TcdB are homologous multi-
domain single-chain proteins of 308 and 270 kDa, respectively. Both
toxins share the same domain architecture. The N-terminus harbors
the catalytic domain, a glucosyltransferase (GTD) acting on small
Rho-GTPases (Just et al., 1995; Busch et al., 1998), followed by a
cysteine protease domain (CPD) catalyzing the proteolytic auto-
processing and upon translocation releasing the GTD into the
cytosol (Egerer et al., 2007; Reineke et al., 2007). Pore formation
and translocation of the N-terminal portion of the toxin is facilitated
by the translocation domain (TLD) (Genisyuerek et al., 2011). The
C-terminus of TcdA and TcdB composes repetitive elements that
combine long and short repeats in so called CROPs (Combined
Repetitive Oligo Peptides). The CROPs are responsible for the first
contact of the toxin with the target cells by interaction with
carbohydrate structures on the cell surface (von Eichel-Streiber
et al., 1992).
Due to increasing CDAD case numbers and epidemic
outbreaks (Rupnik et al., 2009; Depestel and Aronoff, 2013),
these two toxins were targets of several antibody-generation-
campaigns (Babcock et al., 2006; Marozsan et al., 2012). In 2011,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 20Hussack and coworkers were the first to report the successful
generation of anti TcdA antibodies by phage display using a
llama derived immune library. Four VHH antibodies (A4.2, A5.1,
A20.1, and A26.8), showed potent neutralization of the cytopathic
effects of TcdAonfibroblast cells in an in vitro assay (Hussack et al.,
2011). Similarly, Yang et al. used an alpaca derived immune library
to generate six and eleven unique VHH antibodies against TcdA
and TcdB, respectively. The single domain antibodies showing the
most potent neutralizing activity and highest affinity to non-
overlapping epitopes were combined in a tetravalent bispecific
antibody format designated as “ABA”. The heterotetramer ABA
consists of two copies of the anti TcdB VHH E3 as well as the one
copy of each of the anti TcdAVHHsAH3 andAA6 in the following
order: AH3/E3/E3/AA6. ABA was shown to bind to TcdA and
TcdB simultaneously and one single injection of ABA was enough
to reverse fulminant CDAD in mice. In another antibody
generation campaign, the naïve scFv libraries HAL9/10 (Kügler
et al., 2015) were used to isolate the first fully human, phage display
derived antibodies against TcdB. Using various TcdB fragments for
the panning process, partially combined with preincubation steps,
31 unique antibodies were generated directed against a broad range
of epitopes. The antibodies were tested in an in vitro neutralization
assay usingVero cells. Interestingly, the twomost potent antibodies
bound to the same, formerly unknown, epitope within the
glycosyltransferase domain of TcdB (Fühner et al., 2018).
Diphtheria toxin (DT) is a typical A-B-toxin with an A subunit
(catalytic domain) and a B subunit that contains the cell binding
domain and the translocation domain. DT is produced by a
corynephage b infected pathogenic Corynebacterium stain,
mainly Corynebacterium diphtheriae (Murphy, 1996). To date,
the only approved therapeutic is a serum from horses immunized
with diphtheria toxin, as invented by Emil von Behring and
Shibasaburo Kitasato over 100 years ago (von Behring and
Kitasato, 1890). Antibodies were generated by phage display
from immune libraries of boost vaccinated donors. Neutralizing
antibodies against all three domains of DT were selected. The best
antibodies showed an in vitro neutralizing antibody with a relative
potency of 454 IU/mg at 4xMCDt (minimal cytopathic dose).
When using higher toxin concentration, the neutralization
efficacy was highly reduced, but when using two or three
antibodies in combinations the neutralization was restored. An
in vivo potency of 79.4 IU/mg was achieved in an intradermal
challenge assay (Wenzel et al., 2020a).
An Overview of recombinant antibodies against toxins are
given in Table 4.CONCLUSION
A large number of recombinant antibodies for application in
diagnostics and therapy were already generated by phage display
against viral, bacterial and eukaryotic pathogens as well as toxins.
Antibody phage display allows the generation of antibodies
originating from several species, including human, camel,
llama, alpaca, chimpanzee, macaque, pig, mice, chicken or
shark. These antibodies are derived from two types of libraryJuly 2021 | Volume 11 | Article 697876
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type A alpha-toxin semi-
synthetic
scFv human ELISA, in vitro inhibition, in vivo
protection
(Wang D. et al.,
2017)
Anthrax toxin Bacillus anthracis lethal factor (LF) immune scFv macaque ELISA, in vitro toxin
neutralization, in vivo protection
(Pelat et al., 2007)
Anthrax toxin Bacillus anthracis protective antigen
(PA)
naïve scFv human in vitro toxin neutralization, in vivo
protection
(Mazumdar, 2009)
Anthrax toxin Bacillus anthracis protective antigen
(PA)
immune VHH camel ELISA (Shali et al., 2018)
Anthrax toxin Bacillus anthracis lethal factor (LF) immune VHH, bispecific
VHH
alpaca ELISA, WB, in vivo protection (Vrentas et al., 2016)




alpaca ELISA, in vitro inhibition, in vivo
protection





serotype A - light
chain






serotype A - light
chain
immune scFv,scFv-Fc macaque ELISA, WB, in vitro toxin
inhibition, ex vivo toxin
neutralization





serotype A - light
chain






serotype A - heavy
chain








serotype A - heavy
chain








serotype A - heavy
chain








serotype A - heavy
chain
immune scFv macaque ELISA, ex vivo toxin
neutralization





serotype A + B immune scFv-Fc, IgG macaque ELISA, in vivo mouse paralysis
assay, in vivo protection











serotype B - light
chain/heavy chain
immune scFv,scFv-Fc macaque ELISA, in vitro toxin inhibition, ex








serotype E - light
chain
immune scFv,scFv-Fc macaque ELISA, in vitro toxin inhibition, ex
vivo toxin neutralization, in vivo
protection





serotype E - light
chain
immune scFv-Fc, IgG macaque ELISA, in vivo mouse paralysis
assay, in vivo protection





serotype E - heavy
chain








immune VHH llama ELISA, in vitro toxin inhibition (Conway et al.,
2010; Shriver-Lake
et al., 2017)
C. difficile toxin Clostridioides
difficile
TcdA immune VHH llama ELISA, WB, in vitro neutralization (Hussack et al.,
2011)
C. difficile toxin Clostridioides
difficile
TcdA, TcdB immune VHH, bispecific
VHH
alpaca ELISA, in vitro toxin inhibition, in
vivo protection
(Yang et al., 2014)
C. difficile toxin Clostridioides
difficile
TcdB naïve scFv-Fc human dot blot, in vitro neutralization (Chung et al., 2018)
C. difficile toxin Clostridioides
difficile
TcdB naïve scFv, scFv-Fc human ELiSA, in vitro neutralization (Fühner et al., 2018)
C. difficile toxin Clostridium
difficile






immune scFv mice ELISA, sandwich ELISA (Dong et al., 2018)
Cry toxin Bacillus
thuringiensis
Cry1E immune dAb human ELISA, in vitro inhibition (Xu et al., 2017a)
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Cry1F immune scFv rabbit ELISA (Xu et al., 2017b)
Cry toxin Bacillus
thuringiensis



















VHH humanizedcamel ELISA, WB, in vitro neutralization (Malik et al., 2016)
Diphtheria toxin Corynebacterium
diphtheriae
DT immune scFv, scFv-Fc,
IgG
human ELISA, in vitro neutralization, in
vivo neutralization
(Wenzel et al., 2020a)
Enterotoxin B Escherichia coli EtxB semi-
synthetic










scFv human – (Lauer et al., 2005)
Mycotoxin Fusarium spp. trichothecenes HT-2 immune Fab mice TR-FRET Assay (Arola et al., 2016)
Mycotoxin Aspergillus flavus aflatoxin B1 immune VHH alpaca ELISA (He et al., 2014)









microcystin-LR immune scFv rabbit ELISA (Xu et al., 2019)
Microcystin Microcystis
aeruginosa
microcystin-LR immune VHH alpaca ELISA, inhibition ELISA (Xu et al., 2018)
Mycolactone Mycobacterium
ulcerans


























Salmonella Typhi hemolysin E antigen naïve scFv human ELISA, WB (Lim et al., 2016)
Shiga toxin E.coli (STEC) Stx2 semi-
synthetic
Fab human ELISA, WB, in vitro neutralization (Luz et al., 2015)
Shiga toxin E.coli (EHEC) Stx1, Stx2 naïve scFv human ELISA, FACS, in vitro toxin
neutralization
(Neri et al., 2011)















SEB synthetic Fab human ELISA, WB, in vitro toxin
inhibition





















SEB immune VHH camel ELISA (Zanganeh et al.,
2019)
(Continued)Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 22 July 2021 | Volume 11 | Article 697876
Roth et al. Recombinant Antibodies Against Infectious Diseasessources: immune or universal libraries. Immune libraries are
preferred when convalescent patients or immunized animals/
human donors are available. This approach offers the advantage
to directly isolate affinity matured antibodies. Universal antibody
gene libraries offer an alternative if immunization is not possible,
ethically not feasible or patient samples are not available.
The COVID-19 pandemic should teach us to be prepared for
the next pandemic, which beyond any doubt will come. We need
permanent preparedness platforms which will react on novel
pathogens arising worldwide and provide antibodies for
diagnostics and as potential therapeutic lead candidates. This
preparedness platforms should also have a budget for immediate
start of GMP production and clinical phase I/II studies. In the
most cases, new pathogens may have only a local impact, but this
cannot be assured. Also these antibodies are always valuable tools
for research and diagnostics of the pathogens.
We do not build a fire department when the house is already
burning, we need to establish it in advance and maintain this
service also in times without emergency. We have to think in the
same way about infectious diseases and potential pandemics.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 23AUTHOR CONTRIBUTIONS
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